Molecular	O
mechanism	O
of	O
cell	O
cycle	O
progression	O
induced	O
by	O
the	O
oncogene	B-protein
product	I-protein
Tax	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O

The	O
trans-activator	B-protein
protein	I-protein
Tax	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
adult	O
T-cell	O
leukemia	O
through	O
,	O
at	O
least	O
in	O
part	O
,	O
its	O
ability	O
to	O
stimulate	O
cell	O
growth	O
.	O

We	O
previously	O
reported	O
that	O
Tax	B-protein
induced	O
cell	O
cycle	O
progression	O
from	O
G0/G1	O
phase	O
to	O
S	O
and	O
G2/M	O
phases	O
in	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
Kit	I-cell_line
225	I-cell_line
cells	I-cell_line
.	O

To	O
elucidate	O
molecular	O
mechanism	O
of	O
Tax	B-protein
-induced	O
cell	O
cycle	O
progression	O
,	O
we	O
systematically	O
examined	O
the	O
effects	O
of	O
Tax	B-protein
on	O
biochemical	O
events	O
associated	O
with	O
cell	O
cycle	O
progression	O
.	O

Introduction	O
of	O
Tax	B-protein
into	O
resting	B-cell_line
Kit	I-cell_line
225	I-cell_line
cells	I-cell_line
induced	O
activation	O
of	O
the	O
G1/S	O
transition	O
regulation	O
cascade	O
consisting	O
of	O
activation	O
of	O
cyclin	B-protein
dependent	I-protein
kinase	I-protein
2	I-protein
(	O
CDK2	B-protein
)	O
and	O
CDK4	B-protein
,	O
phosphorylation	O
of	O
the	O
Rb	B-protein
family	I-protein
proteins	I-protein
and	O
an	O
increase	O
in	O
free	O
E2F	B-protein
.	O

The	O
kinase	O
activation	O
was	O
found	O
to	O
result	O
from	O
Tax	B-protein
-induced	O
expression	O
of	O
genes	O
for	O
cell	B-protein
cycle	I-protein
regulatory	I-protein
molecules	I-protein
including	O
cyclin	B-protein
D2	I-protein
,	O
cyclin	B-protein
E	I-protein
,	O
E2F1	B-protein
,	O
CDK2	B-protein
,	O
CDK4	B-protein
and	O
CDK6	B-protein
,	O
and	O
Tax	B-protein
-induced	O
reduction	O
of	O
CDK	B-protein
inhibitors	I-protein
p19	I-protein
(	O
INK4d	B-protein
)	O
and	O
p27	B-protein
(	I-protein
Kip1	I-protein
)	I-protein
.	O

These	O
modulations	O
by	O
Tax	B-protein
always	O
paralleled	O
the	O
ability	O
of	O
Tax	B-protein
to	O
activate	O
the	O
NF-kappaB	O
transcription	O
pathway	O
.	O

These	O
results	O
indicate	O
the	O
important	O
role	O
of	O
Tax	B-protein
-mediated	O
trans-activation	O
of	O
the	O
genes	O
for	O
cell	B-protein
cycle	I-protein
regulatory	I-protein
molecules	I-protein
in	O
Tax	B-protein
-induced	O
cell	O
cycle	O
progression	O
.	O

ORIGINAL	NULL
PAPERS	NULL
Oncogene	NULL
(	NULL
2001	NULL
)	NULL
20	NULL
,	NULL
2055-2067	NULL
©	NULL
2001	NULL
Nature	NULL
Publishing	NULL
Group	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/01	NULL
$	NULL
15.00	NULL
www.nature.com/onc	NULL
Molecular	NULL
mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
induced	NULL
by	NULL
the	NULL
oncogene	NULL
product	NULL
Tax	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
Ritsuko	NULL
Iwanaga	NULL
'	NULL
,	NULL
Kiyoshi	NULL
Ohtani*	NULL
'	NULL
,	NULL
Takeshi	NULL
Hayashi	NULL
'	NULL
and	NULL
Masataka	NULL
Nakamura	NULL
'	NULL
'Human	NULL
Gene	NULL
Sciences	NULL
Center	NULL
,	NULL
Tokyo	NULL
Medical	NULL
and	NULL
Dental	NULL
University	NULL
,	NULL
1-5-45	NULL
Yushima	NULL
,	NULL
Bunkyo-ku	NULL
,	NULL
Tokyo	NULL
113-8510	NULL
,	NULL
Japan	NULL
The	NULL
trans-activator	NULL
protein	NULL
Tax	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
through	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
its	NULL
ability	NULL
to	NULL
stimulate	NULL
cell	NULL
growth	NULL
.	NULL

We	NULL
previously	NULL
reported	NULL
that	NULL
Tax	NULL
induced	NULL
cell	NULL
cycle	NULL
progression	NULL
from	NULL
GO0/G1	NULL
phase	NULL
to	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
in	NULL
human	NULL
T-cell	NULL
line	NULL
Kit	NULL
225	NULL
cells	NULL
.	NULL

To	NULL
elucidate	NULL
molecular	NULL
mechanism	NULL
of	NULL
Tax-induced	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
we	NULL
systematically	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
Tax	NULL
on	NULL
biochemical	NULL
events	NULL
associated	NULL
with	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Introduction	NULL
of	NULL
Tax	NULL
into	NULL
resting	NULL
Kit	NULL
225	NULL
cells	NULL
induced	NULL
activation	NULL
of	NULL
the	NULL
G1/S	NULL
transition	NULL
regulation	NULL
cascade	NULL
consisting	NULL
of	NULL
activation	NULL
of	NULL
cyclin	NULL
dependent	NULL
kinase	NULL
2	NULL
(	NULL
CDK2	NULL
)	NULL
and	NULL
CDK4	NULL
,	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
proteins	NULL
and	NULL
an	NULL
increase	NULL
in	NULL
free	NULL
E2F	NULL
.	NULL

The	NULL
kinase	NULL
activation	NULL
was	NULL
found	NULL
to	NULL
result	NULL
from	NULL
-	NULL
Tax-induced	NULL
expression	NULL
of	NULL
genes	NULL
for	NULL
cell	NULL
cycle	NULL
regulatory	NULL
molecules	NULL
including	NULL
cyclin	NULL
D2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
E2F1	NULL
,	NULL
CDK2	NULL
,	NULL
CDK4	NULL
and	NULL
CDK6	NULL
,	NULL
and	NULL
Tax-induced	NULL
reduction	NULL
of	NULL
CDK	NULL
inhibitors	NULL
p19	NULL
``	NULL
~*	NULL
``	NULL
and	NULL
p27	NULL
``	NULL
``	NULL
.	NULL

These	NULL
modulations	NULL
by	NULL
Tax	NULL
always	NULL
paralleled	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
activate	NULL
the	NULL
NF-xB	NULL
transcription	NULL
pathway	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
the	NULL
important	NULL
role	NULL
of	NULL
Tax-mediated	NULL
trans-activation	NULL
of	NULL
the	NULL
genes	NULL
for	NULL
cell	NULL
cycle	NULL
regulatory	NULL
molecules	NULL
in	NULL
Tax-induced	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Oncogene	NULL
(	NULL
2001	NULL
)	NULL
20	NULL
,	NULL
2055-2067	NULL
.	NULL

Keywords	NULL
:	NULL
cell	NULL
cycle	NULL
;	NULL
E2F	NULL
;	NULL
HTLV-I	NULL
;	NULL
NF-xB	NULL
;	NULL
Tax	NULL
;	NULL
cyclin	NULL
D2	NULL
Introduction	NULL
Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
is	NULL
the	NULL
etiological	NULL
agent	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
(	NULL
ATL	NULL
)	NULL
(	NULL
Hinuma	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
;	NULL
Poiesz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1980	NULL
;	NULL
Yoshida	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
,	NULL
and	NULL
HTLV-I-associated	NULL
myelopathy/tropical	NULL
spastic	NULL
paraparesis	NULL
(	NULL
HAM/TSP	NULL
)	NULL
(	NULL
Gessain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Osame	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

Accumulating	NULL
evidence	NULL
displays	NULL
that	NULL
Tax	NULL
encoded	NULL
by	NULL
HTLV-I	NULL
plays	NULL
critical	NULL
roles	NULL
in	NULL
leukemogenesis	NULL
.	NULL

Introduction	NULL
of	NULL
the	NULL
Tax	NULL
gene	NULL
induces	NULL
phenotypic	NULL
transformation	NULL
in	NULL
fibroblast	NULL
cell	NULL
lines	NULL
(	NULL
Tanaka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
persistent	NULL
growth	NULL
of	NULL
primary	NULL
T	NULL
*Correspondence	NULL
:	NULL
K	NULL
Ohtani	NULL
Received	NULL
12	NULL
November	NULL
2000	NULL
;	NULL
revised	NULL
18	NULL
January	NULL
2001	NULL
;	NULL
accepted	NULL
24	NULL
January	NULL
2001	NULL
cells	NULL
in	NULL
vitro	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
Akagi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Grassmann	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
and	NULL
development	NULL
of	NULL
tumors	NULL
and	NULL
leukemia	NULL
in	NULL
mice	NULL
in	NULL
vivo	NULL
(	NULL
Grossman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Nerenberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Tax	NULL
has	NULL
growth	NULL
stimulatory	NULL
properties	NULL
.	NULL

Tax	NULL
was	NULL
initially	NULL
identified	NULL
as	NULL
a	NULL
trans-acting	NULL
transcriptional	NULL
activator	NULL
of	NULL
the	NULL
HTLV-I	NULL
promoter	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
(	NULL
Felber	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Seiki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Sodroski	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

Tax	NULL
was	NULL
subsequently	NULL
demonstrated	NULL
to	NULL
trans-activate	NULL
transcription	NULL
of	NULL
various	NULL
cellular	NULL
genes	NULL
involved	NULL
in	NULL
cell	NULL
growth	NULL
signaling	NULL
,	NULL
such	NULL
as	NULL
genes	NULL
for	NULL
growth	NULL
factors	NULL
,	NULL
growth	NULL
factor	NULL
receptors	NULL
,	NULL
cytoplasmic	NULL
signal	NULL
transmitters	NULL
,	NULL
and	NULL
nuclear	NULL
transcription	NULL
factors	NULL
(	NULL
Yoshida	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Trans-activation	NULL
of	NULL
the	NULL
growth	NULL
related	NULL
cellular	NULL
genes	NULL
by	NULL
Tax	NULL
is	NULL
thought	NULL
to	NULL
make	NULL
cellular	NULL
circumstances	NULL
advantageous	NULL
for	NULL
cell	NULL
growth	NULL
.	NULL

Tax	NULL
is	NULL
considered	NULL
to	NULL
activate	NULL
cellular	NULL
genes	NULL
through	NULL
modulation	NULL
of	NULL
three	NULL
transcription	NULL
factors	NULL
,	NULL
cAMP	NULL
responsive	NULL
element	NULL
binding	NULL
factor	NULL
(	NULL
CREB	NULL
)	NULL
,	NULL
serum	NULL
responsive	NULL
factor	NULL
(	NULL
SRF	NULL
)	NULL
and	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-xB	NULL
(	NULL
Yoshida	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Recent	NULL
findings	NULL
that	NULL
Tax	NULL
can	NULL
interact	NULL
with	NULL
molecules	NULL
involved	NULL
in	NULL
regulation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
suggest	NULL
that	NULL
Tax	NULL
may	NULL
be	NULL
directly	NULL
implicated	NULL
in	NULL
cell	NULL
cycle	NULL
control	NULL
.	NULL

Tax	NULL
binds	NULL
and	NULL
inactivates	NULL
p16	NULL
``	NULL
~**	NULL
,	NULL
and	NULL
suppresses	NULL
expression	NULL
of	NULL
p18	NULL
``	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
inhibitors	NULL
of	NULL
cyclin	NULL
D-dependent	NULL
kinases	NULL
,	NULL
suggesting	NULL
the	NULL
possibility	NULL
that	NULL
Tax	NULL
lowers	NULL
the	NULL
threshold	NULL
of	NULL
activation	NULL
of	NULL
G1	NULL
cyclin	NULL
dependent	NULL
kinases	NULL
(	NULL
CDKs	NULL
)	NULL
(	NULL
Low	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Suzuki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

Collectively	NULL
,	NULL
Tax	NULL
is	NULL
a	NULL
potential	NULL
oncoprotein	NULL
which	NULL
induces	NULL
leukemogenesis	NULL
presumably	NULL
through	NULL
functional	NULL
modulation	NULL
of	NULL
molecules	NULL
and	NULL
genes	NULL
related	NULL
to	NULL
growth	NULL
signaling	NULL
and	NULL
cell	NULL
cycle	NULL
control	NULL
.	NULL

It	NULL
is	NULL
still	NULL
unclear	NULL
how	NULL
Tax-induced	NULL
modulation	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
promotion	NULL
of	NULL
cell	NULL
proliferation	NULL
.	NULL

Cell	NULL
proliferation	NULL
is	NULL
strictly	NULL
controlled	NULL
by	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Progression	NULL
through	NULL
G1	NULL
phase	NULL
into	NULL
S	NULL
phase	NULL
is	NULL
controlled	NULL
by	NULL
CDKs	NULL
which	NULL
associate	NULL
with	NULL
cyclin	NULL
Ds	NULL
and	NULL
cyclin	NULL
E.	NULL
One	NULL
of	NULL
the	NULL
roles	NULL
of	NULL
these	NULL
kinases	NULL
in	NULL
G1/S	NULL
progression	NULL
is	NULL
phosphorylation	NULL
of	NULL
members	NULL
of	NULL
the	NULL
retinoblastoma	NULL
tumor	NULL
suppressor	NULL
protein	NULL
(	NULL
Rb	NULL
)	NULL
family	NULL
,	NULL
pRb	NULL
,	NULL
p130	NULL
and	NULL
p1l07	NULL
,	NULL
consequently	NULL
activating	NULL
the	NULL
transcription	NULL
factor	NULL
E2F	NULL
.	NULL

E2F	NULL
plays	NULL
crucial	NULL
roles	NULL
in	NULL
G1/S	NULL
progression	NULL
by	NULL
regulating	NULL
various	NULL
genes	NULL
which	NULL
encode	NULL
molecules	NULL
involved	NULL
in	NULL
cell	NULL
cycle	NULL
progression	NULL
and	NULL
DNA	NULL
replication	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
use	NULL
human	NULL
T-cells	NULL
arrested	NULL
at	NULL
GO/G1	NULL
phase	NULL
to	NULL
exactly	NULL
evaluate	NULL
effects	NULL
of	NULL
Tax	NULL
on	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Kit	NULL
225	NULL
human	NULL
T-cell	NULL
line	NULL
is	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
2056	NULL
Oh	NULL
24	NULL
h	NULL
48	NULL
h	NULL
72	NULL
h	NULL
Figure	NULL
1	NULL
Kinetics	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
induced	NULL
by	NULL
Tax	NULL
.	NULL

recombinant	NULL
viruses	NULL
.	NULL

Kit	NULL
225	NULL
cells	NULL
starved	NULL
of	NULL
IL-2	NULL
for	NULL
48	NULL
h	NULL
(	NULL
0	NULL
h	NULL
Cell	NULL
number	NULL
Cell	NULL
number	NULL
Cell	NULL
number	NULL
Cell	NULL
number	NULL
ao	NULL
)	NULL
s	NULL
14.9	NULL
%	NULL
#	NULL
I	NULL
--	NULL
i	NULL
8°	NULL
ans	NULL
Sto	NULL
-	NULL
sha	NULL
``	NULL
wto	NULL
DNA	NULL
content	NULL
IL-2-	NULL
IL-2+	NULL
Con	NULL
Tax	NULL
Taxd17/5	NULL
L	NULL
Taxd3	NULL
L	NULL
TaxM22	NULL
&	NULL
8	NULL
&	NULL
8	NULL
&	NULL
--	NULL
B	NULL
2	NULL
B	NULL
s	NULL
¢	NULL
®	NULL
|	NULL
t	NULL
x	NULL
8	NULL
3	NULL
68.7	NULL
B	NULL
8	NULL
s	NULL
B	NULL
|	NULL
a	NULL
®	NULL
®	NULL
&	NULL
#	NULL
10	NULL
;	NULL
#	NULL
a	NULL
#	NULL
13.0	NULL
%	NULL
111	NULL
%	NULL
11.0	NULL
%	NULL
12.5	NULL
%	NULL
l	NULL
|	NULL
1089	NULL
h	NULL
=	NULL
--	NULL
#	NULL
a	NULL
-	NULL
#	NULL
I-A	NULL
#	NULL
a	NULL
¢	NULL
I-\	NULL
.	NULL

*I	NULL
sam	NULL
w	NULL
w	NULL
ih	NULL
-	NULL
``	NULL
C	NULL
B	NULL
WTH	NULL
ch	NULL
ihe	NULL
0	NULL
G	NULL
HB	NULL
H	NULL
o	NULL
te	NULL
ide	NULL
R	NULL
5	NULL
we	NULL
an	NULL
iin	NULL
II	NULL
ai	NULL
oo	NULL
wo	NULL
wn	NULL
THB	NULL
T2	NULL
ue	NULL
we	NULL
i	NULL
FZIMCCOMCT	NULL
AOE	NULL
IMEC	NULL
J	NULL
DNA	NULL
content	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
8	NULL
&	NULL
E	NULL
h	NULL
2	NULL
2	NULL
#	NULL
34	NULL
B	NULL
-	NULL
#	NULL
47	NULL
.	NULL

*	NULL
A	NULL
#	NULL
a	NULL
*	NULL
12.00	NULL
Ct	NULL
152	NULL
%	NULL
19.7	NULL
%	NULL
102	NULL
%	NULL
16.8	NULL
%	NULL
,	NULL
|	NULL
115	NULL
%	NULL
#	NULL
#	NULL
he	NULL
#	NULL
#	NULL
I	NULL
--	NULL
#	NULL
-I	NULL
#	NULL
i-a	NULL
11	NULL
Js	NULL
tome	NULL
``	NULL
T	NULL
mo	NULL
T	NULL
whi	NULL
ima	NULL
®	NULL
He	NULL
``	NULL
ato	NULL
``	NULL
ide	NULL
``	NULL
``	NULL
olo	NULL
e	NULL
``	NULL
Kad	NULL
an	NULL
``	NULL
``	NULL
ote	NULL
``	NULL
ue	NULL
mo	NULL
``	NULL
sio	NULL
``	NULL
Me	NULL
``	NULL
ime	NULL
e	NULL
-am	NULL
-	NULL
t	NULL
.	NULL

ih	NULL
uite	NULL
'	NULL
e	NULL
``	NULL
``	NULL
ad	NULL
``	NULL
ale	NULL
ali	NULL
whe	NULL
Hs	NULL
-do	NULL
sis	NULL
son	NULL
wie	NULL
DNA	NULL
content	NULL
&	NULL
&	NULL
&	NULL
5	NULL
&	NULL
&	NULL
8	NULL
be	NULL
®	NULL
8	NULL
s	NULL
3	NULL
#	NULL
B	NULL
8	NULL
&	NULL
B	NULL
&	NULL
8	NULL
8	NULL
8	NULL
|	NULL
*	NULL
ak	NULL
24.3	NULL
%	NULL
®	NULL
8	NULL
184	NULL
%	NULL
®	NULL
12	NULL
%	NULL
11.0	NULL
%	NULL
128	NULL
%	NULL
12.0	NULL
%	NULL
®	NULL
-	NULL
i	NULL
#	NULL
#	NULL
L	NULL
I-A	NULL
#	NULL
I-	NULL
#	NULL
I-Mimi	NULL
avemsad	NULL
binte	NULL
.	NULL

hz	NULL
WWW	NULL
ll	NULL
ed	NULL
$	NULL
0	NULL
me	NULL
ab	NULL
h	NULL
th	NULL
Tum	NULL
°	NULL
me	NULL
ao	NULL
we	NULL
8:0	NULL
won	NULL
we	NULL
-	NULL
alo	NULL
alo	NULL
she	NULL
to	NULL
mo	NULL
an	NULL
sto	NULL
tto	NULL
toto	NULL
5	NULL
``	NULL
ate	NULL
dd	NULL
``	NULL
``	NULL
che	NULL
-	NULL
$	NULL
t	NULL
ite	NULL
60	NULL
me	NULL
do	NULL
un	NULL
ah	NULL
lie	NULL
o	NULL
sh	NULL
we	NULL
g	NULL
me	NULL
min	NULL
DNA	NULL
content	NULL
B	NULL
Tax	NULL
-	NULL
a	NULL
Tax	NULL
+	NULL
8	NULL
&	NULL
84	NULL
81	NULL
€4	NULL
coo	NULL
no	NULL
c	NULL
@	NULL
©	NULL
a	NULL
s	NULL
}	NULL
a	NULL
§	NULL
]	NULL
8	NULL
al	NULL
2	NULL
70.4	NULL
2	NULL
8	NULL
a	NULL
®	NULL
24	NULL
h	NULL
a	NULL
2	NULL
5	NULL
_	NULL
g	NULL
4	NULL
,	NULL
20.5	NULL
%	NULL
5	NULL
*	NULL
=	NULL
#	NULL
C	NULL
-	NULL
C	NULL
s	NULL
3	NULL
H	NULL
``	NULL
3	NULL
3	NULL
*	NULL
N	NULL
2	NULL
}	NULL
7.6	NULL
%	NULL
#	NULL
1	NULL
aim/r	NULL
©	NULL
=	NULL
a	NULL
r	NULL
7	NULL
f	NULL
T	NULL
I	NULL
t	NULL
?	NULL

i	NULL
7	NULL
it	NULL
0	NULL
wo	NULL
iG	NULL
as	NULL
as	NULL
200	NULL
-	NULL
«	NULL
bo	NULL
-	NULL
sto	NULL
-	NULL
$	NULL
00	NULL
.	NULL

1000	NULL
6	NULL
ao	NULL
abs	NULL
-	NULL
abo	NULL
-	NULL
ado	NULL
.	NULL

tooo	NULL
Tax	NULL
DNA	NULL
content	NULL
DNA	NULL
content	NULL
Tax	NULL
-	NULL
Tax	NULL
+	NULL
P	NULL
F	NULL
&	NULL
7	NULL
~	NULL
R	NULL
a	NULL
BB	NULL
BE	NULL
500	NULL
t.	NULL
&	NULL
.	NULL

Eq	NULL
©	NULL
$	NULL
.	NULL

57.8	NULL
%	NULL
$	NULL
&	NULL
g	NULL
]	NULL
§	NULL
``	NULL
42	NULL
3	NULL
§	NULL
``	NULL
3	NULL
1070	NULL
C	NULL
C	NULL
agh	NULL
0	NULL
@	NULL
|	NULL
A	NULL
``	NULL
``	NULL
2	NULL
ce	NULL
a	NULL
``	NULL
&	NULL
©	NULL
lns	NULL
O	NULL
&	NULL
35.0	NULL
%	NULL
«	NULL
i	NULL
©	NULL
®	NULL
r	NULL
1	NULL
'	NULL
w	NULL
t	NULL
wt	NULL
ast	NULL
6	NULL
~	NULL
zbo	NULL
abo	NULL
sto	NULL
-	NULL
abo	NULL
.	NULL

100	NULL
Tax	NULL
DNA	NULL
content	NULL
DNA	NULL
content	NULL
Tax	NULL
-	NULL
Tax	NULL
+	NULL
§	NULL
&	NULL
8	NULL
BB	NULL
2	NULL
EB	NULL
E	NULL
49.0	NULL
%	NULL
5	NULL
g	NULL
5	NULL
.	NULL

a	NULL
§	NULL
!	NULL

§	NULL
§	NULL
41	NULL
-	NULL
]	NULL
§	NULL
®	NULL
ch	NULL
72	NULL
h	NULL
2	NULL
49.0	NULL
%	NULL
2	NULL
2	NULL
_	NULL
=	NULL
#	NULL
2	NULL
&	NULL
]	NULL
=	NULL
&	NULL
m	NULL
=	NULL
©	NULL
8	NULL
$	NULL
l	NULL
|e	NULL
#	NULL
1	NULL
#	NULL
1	NULL
7.1	NULL
%	NULL
#	NULL
1	NULL
``	NULL
D	NULL
CT	NULL
OCF	NULL
f	NULL
on	NULL
8	NULL
200	NULL
abo	NULL
'	NULL
oto	NULL
~	NULL
sho	NULL
(	NULL
doe	NULL
6	NULL
zo	NULL
abs	NULL
aio	NULL
ooo	NULL
ithe	NULL
Tax	NULL
DNA	NULL
content	NULL
DNA	NULL
content	NULL
Oncogene	NULL
(	NULL
A	NULL
)	NULL
Cell	NULL
cycle	NULL
progression	NULL
of	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
Tax	NULL
in	NULL
figure	NULL
)	NULL
were	NULL
infected	NULL
with	NULL
indicated	NULL
recombinant	NULL
adenoviruses	NULL
for	NULL
Tax	NULL
expression	NULL
;	NULL
AxCAIY-Tax	NULL
,	NULL
AxCAIY-Taxd17/5	NULL
,	NULL
AxCAIY-Taxd3	NULL
and	NULL
AxCAIY-TaxM22	NULL
.	NULL

A	NULL
control	NULL
virus	NULL
(	NULL
Ad-Con	NULL
)	NULL
was	NULL
also	NULL
used	NULL
.	NULL

Cells	NULL
were	NULL
further	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
for	NULL
24	NULL
,	NULL
48	NULL
and	NULL
72	NULL
h.	NULL
As	NULL
controls	NULL
,	NULL
mock	NULL
infected	NULL
cells	NULL
were	NULL
either	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
for	NULL
staining	NULL
DNA	NULL
with	NULL
propidium	NULL
iodide	NULL
,	NULL
followed	NULL
by	NULL
flow	NULL
suitable	NULL
for	NULL
this	NULL
purpose	NULL
,	NULL
because	NULL
it	NULL
can	NULL
be	NULL
made	NULL
quiescent	NULL
by	NULL
deprivation	NULL
of	NULL
IL-2	NULL
(	NULL
Hori	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

We	NULL
have	NULL
reported	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
Tax	NULL
in	NULL
quiescent	NULL
Kit	NULL
225	NULL
cells	NULL
induced	NULL
activation	NULL
of	NULL
endogenous	NULL
E2F	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
to	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
(	NULL
Ohtani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
phytohemagglutinin-stimulated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
,	NULL
which	NULL
also	NULL
grow	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
stimulate	NULL
cell	NULL
cycle	NULL
progression	NULL
is	NULL
not	NULL
specific	NULL
to	NULL
Kit	NULL
225	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
systematically	NULL
examined	NULL
Tax-induced	NULL
biochemical	NULL
events	NULL
leading	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
E2F	NULL
with	NULL
IL-2-starved	NULL
Kit	NULL
225	NULL
cells	NULL
.	NULL

Our	NULL
results	NULL
demonstrate	NULL
that	NULL
Tax	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
group	NULL
of	NULL
cellular	NULL
genes	NULL
encoding	NULL
molecules	NULL
for	NULL
cell	NULL
cycle	NULL
control	NULL
including	NULL
genes	NULL
for	NULL
cyclin	NULL
D2	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
CDK2	NULL
and	NULL
CDK4	NULL
.	NULL

As	NULL
a	NULL
consequence	NULL
,	NULL
CDK2	NULL
and	NULL
CDK4	NULL
are	NULL
activated	NULL
,	NULL
leading	NULL
to	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
proteins	NULL
and	NULL
augmentation	NULL
of	NULL
free	NULL
E2F	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
Tax	NULL
mutants	NULL
to	NULL
induce	NULL
these	NULL
events	NULL
always	NULL
parallels	NULL
the	NULL
activation	NULL
of	NULL
NF-xB	NULL
transcription	NULL
pathway	NULL
and	NULL
promotion	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

This	NULL
implies	NULL
that	NULL
Tax	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
cell	NULL
cycle	NULL
progression	NULL
through	NULL
trans-activating	NULL
cell	NULL
cycle	NULL
regulatory	NULL
genes	NULL
.	NULL

Results	NULL
Kinetics	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
induced	NULL
by	NULL
infection	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
We	NULL
previously	NULL
reported	NULL
that	NULL
expression	NULL
of	NULL
HTLV-I	NULL
Tax	NULL
in	NULL
the	NULL
human	NULL
T-cell	NULL
line	NULL
Kit	NULL
225	NULL
,	NULL
which	NULL
was	NULL
made	NULL
quiescent	NULL
by	NULL
deprivation	NULL
of	NULL
IL-2	NULL
,	NULL
caused	NULL
cell	NULL
cycle	NULL
progression	NULL
at	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
Tax-expressing	NULL
recombinant	NULL
adenovirus	NULL
(	NULL
Ohtani	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
biochemical	NULL
events	NULL
associated	NULL
with	NULL
Tax-induced	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
we	NULL
first	NULL
compared	NULL
the	NULL
kinetics	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
induced	NULL
by	NULL
Tax	NULL
with	NULL
that	NULL
by	NULL
IL-2	NULL
.	NULL

Kit	NULL
225	NULL
cells	NULL
were	NULL
IL-2-starved	NULL
for	NULL
48	NULL
h	NULL
and	NULL
Tax	NULL
was	NULL
introduced	NULL
by	NULL
infection	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
(	NULL
AxCAIY-Tax	NULL
)	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
mock	NULL
infected	NULL
cells	NULL
were	NULL
either	NULL
kept	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
examined	NULL
for	NULL
cell	NULL
cycle	NULL
properties	NULL
.	NULL

Restimulation	NULL
with	NULL
IL-2	NULL
for	NULL
24	NULL
h	NULL
dramatically	NULL
increased	NULL
population	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
(	NULL
from	NULL
14.9	NULL
to	NULL
63.7	NULL
%	NULL
)	NULL
,	NULL
which	NULL
declined	NULL
to	NULL
47.9	NULL
%	NULL
at	NULL
48	NULL
h	NULL
and	NULL
36.7	NULL
%	NULL
at	NULL
72	NULL
h	NULL
post	NULL
stimulation	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

Cells	NULL
kept	NULL
IL-2-starved	NULL
for	NULL
72	NULL
h	NULL
showed	NULL
a	NULL
small	NULL
population	NULL
(	NULL
down	NULL
to	NULL
11	NULL
%	NULL
)	NULL
in	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
.	NULL

Infection	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
did	NULL
not	NULL
change	NULL
the	NULL
population	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
until	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
.	NULL

Afterwards	NULL
,	NULL
the	NULL
population	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
increased	NULL
with	NULL
time	NULL
;	NULL
up	NULL
to	NULL
19.7	NULL
and	NULL
24.3	NULL
%	NULL
at	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
,	NULL
respectively	NULL
,	NULL
while	NULL
infection	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
with	NULL
a	NULL
control	NULL
virus	NULL
did	NULL
not	NULL
show	NULL
any	NULL
appreciable	NULL
change	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
cell	NULL
cycle	NULL
progression	NULL
induced	NULL
by	NULL
Tax	NULL
is	NULL
a	NULL
gradual	NULL
process	NULL
as	NULL
compared	NULL
to	NULL
that	NULL
induced	NULL
by	NULL
IL-2	NULL
.	NULL

To	NULL
address	NULL
the	NULL
reason	NULL
of	NULL
the	NULL
slow	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
kinetics	NULL
of	NULL
Tax	NULL
expression	NULL
in	NULL
the	NULL
virus	NULL
infected	NULL
cells	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
(	NULL
FACS	NULL
)	NULL
analysis	NULL
.	NULL

A	NULL
small	NULL
portion	NULL
(	NULL
20.5	NULL
%	NULL
)	NULL
of	NULL
Kit	NULL
225	NULL
cells	NULL
was	NULL
positive	NULL
for	NULL
Tax	NULL
at	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Tax	NULL
positive	NULL
cells	NULL
increased	NULL
to	NULL
42	NULL
%	NULL
at	NULL
48	NULL
h	NULL
and	NULL
49	NULL
%	NULL
at	NULL
72	NULL
h.	NULL
These	NULL
results	NULL
indicate	NULL
that	NULL
more	NULL
than	NULL
24	NULL
h	NULL
was	NULL
required	NULL
for	NULL
maximum	NULL
expression	NULL
of	NULL
Tax	NULL
when	NULL
Tax	NULL
was	NULL
introduced	NULL
by	NULL
adenovirus	NULL
infection	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
even	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
only	NULL
half	NULL
the	NULL
population	NULL
of	NULL
Kit	NULL
225	NULL
cells	NULL
were	NULL
positive	NULL
for	NULL
Tax	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
,	NULL
presumably	NULL
reflecting	NULL
infection	NULL
efficiency	NULL
.	NULL

The	NULL
population	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G2/	NULL
M	NULL
phases	NULL
did	NULL
not	NULL
further	NULL
increase	NULL
at	NULL
later	NULL
time	NULL
points	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

When	NULL
Tax	NULL
positive	NULL
cells	NULL
were	NULL
gated	NULL
,	NULL
the	NULL
population	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
was	NULL
24.5	NULL
%	NULL
at	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
and	NULL
increased	NULL
up	NULL
to	NULL
35	NULL
%	NULL
at	NULL
48	NULL
h	NULL
and	NULL
40.3	NULL
%	NULL
at	NULL
72	NULL
h	NULL
,	NULL
indicating	NULL
a	NULL
time	NULL
lag	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
after	NULL
Tax	NULL
expression	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
a	NULL
cascade	NULL
of	NULL
events	NULL
is	NULL
induced	NULL
by	NULL
Tax	NULL
for	NULL
the	NULL
cell	NULL
cycle	NULL
to	NULL
be	NULL
promoted	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
results	NULL
,	NULL
biochemical	NULL
events	NULL
associated	NULL
with	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
were	NULL
examined	NULL
24	NULL
h	NULL
,	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
Tax	NULL
recombinant	NULL
viruses	NULL
.	NULL

As	NULL
reported	NULL
previously	NULL
(	NULL
Ohtani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
infection	NULL
with	NULL
a	NULL
mutant	NULL
Tax	NULL
recombinant	NULL
adenovirus	NULL
(	NULL
AxCAIY-Taxd3	NULL
)	NULL
capable	NULL
of	NULL
activating	NULL
the	NULL
NF-xB	NULL
and	NULL
SRF	NULL
pathways	NULL
but	NULL
not	NULL
CREB	NULL
pathway	NULL
promoted	NULL
cell	NULL
cycle	NULL
progression	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

Whereas	NULL
another	NULL
Tax	NULL
mutant	NULL
(	NULL
AxCAIY-Taxd17/5	NULL
)	NULL
incapable	NULL
of	NULL
activating	NULL
any	NULL
of	NULL
these	NULL
pathways	NULL
was	NULL
ineffective	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
NF-xB	NULL
pathway	NULL
or	NULL
SRF	NULL
pathway	NULL
is	NULL
responsible	NULL
for	NULL
Tax-mediated	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
another	NULL
recombinant	NULL
adenovirus	NULL
(	NULL
AxCAIY-TaxM22	NULL
)	NULL
carrying	NULL
a	NULL
mutant	NULL
Tax	NULL
gene	NULL
capable	NULL
of	NULL
activating	NULL
the	NULL
CREB	NULL
and	NULL
SRF	NULL
pathways	NULL
but	NULL
not	NULL
NF-xB	NULL
pathway	NULL
.	NULL

No	NULL
significant	NULL
increase	NULL
in	NULL
the	NULL
population	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
was	NULL
seen	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
AxCAIY-TaxM22	NULL
virus	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
showed	NULL
amounts	NULL
of	NULL
Tax	NULL
and	NULL
mutant	NULL
Tax	NULL
proteins	NULL
were	NULL
comparable	NULL
among	NULL
cells	NULL
infected	NULL
with	NULL
these	NULL
viruses	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
induce	NULL
cell	NULL
cycle	NULL
progression	NULL
coincides	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
activate	NULL
the	NULL
NF-xB	NULL
pathway	NULL
as	NULL
far	NULL
as	NULL
examined	NULL
.	NULL

Increase	NULL
in	NULL
free	NULL
E2F	NULL
by	NULL
Tax	NULL
Since	NULL
Tax	NULL
activated	NULL
endogenous	NULL
E2F	NULL
activity	NULL
in	NULL
IL-2-starved	NULL
Kit	NULL
225	NULL
cells	NULL
(	NULL
Ohtani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
we	NULL
addressed	NULL
the	NULL
question	NULL
of	NULL
how	NULL
Tax	NULL
affected	NULL
expression	NULL
of	NULL
the	NULL
E2F	NULL
cytometric	NULL
examination	NULL
.	NULL

Populations	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
were	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cell	NULL
cycle	NULL
progression	NULL
in	NULL
Tax-expressing	NULL
cells	NULL
.	NULL

Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
AxCAIY-Tax	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
were	NULL
stained	NULL
for	NULL
Tax	NULL
and	NULL
DNA	NULL
with	NULL
anti-Tax	NULL
monoclonal	NULL
antibody	NULL
,	NULL
Lt-4	NULL
,	NULL
and	NULL
propidium	NULL
iodide	NULL
,	NULL
respectively	NULL
.	NULL

Cells	NULL
expressing	NULL
(	NULL
Tax	NULL
+	NULL
)	NULL
and	NULL
not	NULL
expressing	NULL
Tax	NULL
(	NULL
Tax	NULL
-	NULL
)	NULL
were	NULL
gated	NULL
and	NULL
examined	NULL
for	NULL
DNA	NULL
content	NULL
with	NULL
a	NULL
flow	NULL
cytometer	NULL
.	NULL

Populations	NULL
of	NULL
cells	NULL
positive	NULL
and	NULL
negative	NULL
for	NULL
Tax	NULL
and	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
were	NULL
indicated	NULL
2057	NULL
Oncogene	NULL
2058	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
family	NULL
members	NULL
.	NULL

E2F	NULL
1	NULL
mRNA	NULL
levels	NULL
increased	NULL
3.5-fold	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
Tax	NULL
recombinant	NULL
virus	NULL
at	NULL
24	NULL
h	NULL
and	NULL
further	NULL
increased	NULL
4.5-	NULL
and	NULL
3.6-folds	NULL
at	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
mRNAs	NULL
were	NULL
normalized	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
GAPDH	NULL
mRNA	NULL
as	NULL
stimulation	NULL
with	NULL
IL-2	NULL
or	NULL
Tax	NULL
also	NULL
increased	NULL
GAPDH	NULL
mRNA	NULL
.	NULL

A	NULL
slight	NULL
increase	NULL
(	NULL
up	NULL
to	NULL
1.5-fold	NULL
)	NULL
was	NULL
observed	NULL
with	NULL
E2F4	NULL
mRNA	NULL
at	NULL
48	NULL
h.	NULL
In	NULL
contrast	NULL
,	NULL
E2F2	NULL
mRNA	NULL
levels	NULL
clearly	NULL
decreased	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
to	NULL
24	NULL
and	NULL
19	NULL
%	NULL
at	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
,	NULL
respectively	NULL
.	NULL

E2F3	NULL
mRNA	NULL
levels	NULL
did	NULL
not	NULL
change	NULL
significantly	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
showed	NULL
increase	NULL
in	NULL
E2F1	NULL
protein	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

The	NULL
status	NULL
of	NULL
endogenous	NULL
E2F	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
viruses	NULL
was	NULL
further	NULL
examined	NULL
using	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
with	NULL
a	NULL
probe	NULL
of	NULL
the	NULL
typical	NULL
E2F	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
DHFR	NULL
gene	NULL
(	NULL
Ikeda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

A	NULL
major	NULL
complex	NULL
,	NULL
in	NULL
cell	NULL
lysate	NULL
from	NULL
IL-2-starved	NULL
Kit	NULL
225	NULL
cells	NULL
,	NULL
was	NULL
confirmed	NULL
by	NULL
supershift	NULL
with	NULL
antibodies	NULL
to	NULL
be	NULL
the	NULL
p130	NULL
complex	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
dominant	NULL
in	NULL
quiescent	NULL
cells	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
B	NULL
,	NULL
left	NULL
panels	NULL
)	NULL
(	NULL
Smith	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Free	NULL
E2F	NULL
was	NULL
scarcely	NULL
detected	NULL
in	NULL
quiescent	NULL
Kit	NULL
225	NULL
cells	NULL
.	NULL

Importantly	NULL
,	NULL
a	NULL
complex	NULL
containing	NULL
free	NULL
E2F4	NULL
A	NULL
24	NULL
h	NULL
10+	NULL
gag	NULL
1	NULL
au	NULL
v	NULL
5x3	NULL
$	NULL
§	NULL
&	NULL
a	NULL
o	NULL
1	NULL
1	NULL
o	NULL
R	NULL
&	NULL
E	NULL
&	NULL
=	NULL
!	NULL

a=	NULL
»	NULL
24	NULL
h	NULL
IL-2	NULL
IL-2	NULL
+	NULL
Con	NULL
Tax	NULL
Taxd17/5	NULL
Taxd3	NULL
TaxM22	NULL
IL-2	NULL
E2F1	NULL
IL-2	NULL
+	NULL
Con	NULL
Tax	NULL
IL-2	NULL
+	NULL
was	NULL
evident	NULL
with	NULL
lysates	NULL
from	NULL
cells	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
Tax	NULL
recombinant	NULL
virus	NULL
.	NULL

Tax	NULL
induced	NULL
decrease	NULL
in	NULL
p130	NULL
complex	NULL
and	NULL
formation	NULL
of	NULL
the	NULL
slowest	NULL
migration	NULL
complex	NULL
(	NULL
S	NULL
phase	NULL
complex	NULL
)	NULL
,	NULL
which	NULL
was	NULL
either	NULL
supershifted	NULL
or	NULL
abolished	NULL
by	NULL
addition	NULL
of	NULL
antibodies	NULL
against	NULL
p130	NULL
,	NULL
p107	NULL
,	NULL
E2F4	NULL
,	NULL
CDK2	NULL
and	NULL
cyclin	NULL
A	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
complex	NULL
contained	NULL
p130	NULL
,	NULL
p107	NULL
,	NULL
E2F4	NULL
,	NULL
CDK2	NULL
and	NULL
cyclin	NULL
A	NULL
.	NULL

No	NULL
appreciable	NULL
change	NULL
was	NULL
observed	NULL
in	NULL
cells	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
Tax	NULL
recombinant	NULL
virus	NULL
.	NULL

Similar	NULL
complex	NULL
formation	NULL
was	NULL
seen	NULL
with	NULL
cells	NULL
stimulated	NULL
with	NULL
IL-2	NULL
with	NULL
advanced	NULL
kinetics	NULL
(	NULL
Figure	NULL
3A	NULL
left	NULL
panel	NULL
and	NULL
B	NULL
middle	NULL
panel	NULL
)	NULL
.	NULL

Since	NULL
it	NULL
was	NULL
found	NULL
that	NULL
among	NULL
the	NULL
E2F	NULL
family	NULL
only	NULL
E2F4	NULL
was	NULL
detected	NULL
as	NULL
a	NULL
free	NULL
molecule	NULL
,	NULL
we	NULL
tried	NULL
to	NULL
detect	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
other	NULL
members	NULL
of	NULL
the	NULL
E2F	NULL
family	NULL
.	NULL

To	NULL
release	NULL
E2F	NULL
from	NULL
the	NULL
complexes	NULL
with	NULL
Rb	NULL
family	NULL
proteins	NULL
,	NULL
cell	NULL
lysates	NULL
were	NULL
pretreated	NULL
with	NULL
deoxycholic	NULL
acid	NULL
(	NULL
DOC	NULL
)	NULL
.	NULL

Even	NULL
after	NULL
treatment	NULL
with	NULL
DOC	NULL
,	NULL
binding	NULL
activities	NULL
of	NULL
E2F1	NULL
,	NULL
E2F2	NULL
and	NULL
E2F3	NULL
were	NULL
only	NULL
detected	NULL
as	NULL
supershifts	NULL
with	NULL
antibodies	NULL
against	NULL
those	NULL
E2F	NULL
molecules	NULL
(	NULL
Figure	NULL
3B	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

Under	NULL
the	NULL
same	NULL
conditions	NULL
,	NULL
E2F4	NULL
binding	NULL
activity	NULL
increased	NULL
with	NULL
time	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
Tax	NULL
48	NULL
h	NULL
72	NULL
h	NULL
Taxd17/5	NULL
Taxd3	NULL
TaxM22	NULL
IL-2	NULL
+	NULL
Con	NULL
Tax	NULL
Taxd17/5	NULL
Taxd3	NULL
TaxM22	NULL
IL-2	NULL
48	NULL
h	NULL
72	NULL
h	NULL
E	NULL
,	NULL
g	NULL
E	NULL
.	NULL

g	NULL
5	NULL
g	NULL
S	NULL
a	NULL
&	NULL
5	NULL
$	NULL
T	NULL
6	NULL
8	NULL
8	NULL
5	NULL
3	NULL
%	NULL
4	NULL
§	NULL
x	NULL
8	NULL
5	NULL
3	NULL
o	NULL
-	NULL
E	NULL
E	NULL
1	NULL
1	NULL
0	NULL
E-	NULL
-	NULL
r	NULL
t	NULL
Figure	NULL
2	NULL
Effects	NULL
of	NULL
Tax	NULL
on	NULL
expression	NULL
of	NULL
E2F	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
of	NULL
Tax	NULL
on	NULL
the	NULL
E2F	NULL
genes	NULL
.	NULL

mRNAs	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
indicated	NULL
Tax	NULL
recombinant	NULL
adenoviruses	NULL
and	NULL
mock	NULL
infected	NULL
cells	NULL
left	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
as	NULL
in	NULL
Figure	NULL
1A	NULL
were	NULL
analysed	NULL
by	NULL
Northern	NULL
blotting	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
mRNA	NULL
from	NULL
cells	NULL
IL-2-starved	NULL
for	NULL
48	NULL
h	NULL
(	NULL
0	NULL
h	NULL
in	NULL
figure	NULL
)	NULL
was	NULL
also	NULL
used	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
E2F1	NULL
expression	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
indicated	NULL
recombinant	NULL
adenoviruses	NULL
and	NULL
cells	NULL
left	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
as	NULL
in	NULL
Figure	NULL
1A	NULL
Oncogene	NULL
recombinant	NULL
virus	NULL
.	NULL

recombinant	NULL
virus	NULL
.	NULL

A	NULL
Probe	NULL
only	NULL
24	NULL
h	NULL
48	NULL
h	NULL
72	NULL
h	NULL
1	NULL
9	NULL
5	NULL
a	NULL
&	NULL
Antibodies	NULL
>	NULL
a	NULL
.	NULL

2	NULL
£	NULL
@	NULL
IL-2	NULL
These	NULL
results	NULL
expression	NULL
of	NULL
Tax	NULL
leads	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
total	NULL
and	NULL
free	NULL
E2F4	NULL
binding	NULL
activity	NULL
.	NULL

All	NULL
of	NULL
these	NULL
changes	NULL
were	NULL
also	NULL
induced	NULL
by	NULL
infection	NULL
with	NULL
the	NULL
mutant	NULL
Taxd3	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
indicate	NULL
that	NULL
the	NULL
Phosphorylation	NULL
of	NULL
Rb	NULL
family	NULL
proteins	NULL
induced	NULL
by	NULL
Tax	NULL
The	NULL
observation	NULL
that	NULL
Tax	NULL
enhanced	NULL
E2F	NULL
activity	NULL
also	NULL
prompted	NULL
us	NULL
to	NULL
examine	NULL
the	NULL
phosphorylation	NULL
status	NULL
of	NULL
Rb	NULL
family	NULL
members	NULL
,	NULL
pRb	NULL
,	NULL
p130	NULL
and	NULL
p107	NULL
.	NULL

Western	NULL
blot	NULL
+	NULL
4	NULL
g.	NULL
a	NULL
€	NULL
E	NULL
fed	NULL
6	NULL
O	NULL
2	NULL
_	NULL
a	NULL
&	NULL
g	NULL
o	NULL
ais	NULL
.	NULL

lass	NULL
.	NULL

ies	NULL
yaa	NULL
5x	NULL
§	NULL
5	NULL
R	NULL
34458553	NULL
-	NULL
=	NULL
=	NULL
G	NULL
|	NULL
iC	NULL
|C	NULL
C	NULL
=	NULL
1	NULL
11	NULL
G	NULL
°	NULL
iC	NULL
|C	NULL
|C	NULL
-	NULL
S	NULL
phase	NULL
-	NULL
p130	NULL
-	NULL
E2F4	NULL
-	NULL
E2F4	NULL
-	NULL
S	NULL
phase	NULL
-	NULL
p130	NULL
-	NULL
E2F4	NULL
-	NULL
E2F4	NULL
-	NULL
S	NULL
phase	NULL
j	NULL
-	NULL
p130	NULL
-	NULL
E2F4	NULL
-	NULL
E2F4	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
B	NULL
9	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
DOC	NULL
-	NULL
DOC	NULL
+	NULL
<	NULL
&	NULL
§§	NULL
59	NULL
Antibodies	NULL
»	NULL
a	NULL
£	NULL
a	NULL
wu	NULL
0	NULL
O	NULL
Antibodies	NULL
*	NULL
w	NULL
u	NULL
w	NULL
ud	NULL
IL-2	NULL
+	NULL
IL-2	NULL
+	NULL
-	NULL
p130	NULL
-	NULL
E2F4	NULL
Tax	NULL
Tax	NULL
-	NULL
E2F4	NULL
DOC	NULL
+	NULL
Figure	NULL
3	NULL
Effects	NULL
of	NULL
Tax	NULL
on	NULL
complex	NULL
formation	NULL
of	NULL
endogenous	NULL
E2F	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
of	NULL
Tax	NULL
on	NULL
E2F	NULL
binding	NULL
activity	NULL
.	NULL

Whole	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
indicated	NULL
Tax	NULL
recombinant	NULL
adenoviruses	NULL
and	NULL
cells	NULL
left	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
as	NULL
in	NULL
Figure	NULL
1A	NULL
.	NULL

E2F	NULL
binding	NULL
activity	NULL
in	NULL
the	NULL
lysates	NULL
were	NULL
examined	NULL
by	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
using	NULL
typical	NULL
E2F	NULL
sites	NULL
from	NULL
DHFR	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
without	NULL
(	NULL
DOC	NULL
-	NULL
)	NULL
or	NULL
with	NULL
(	NULL
DOC	NULL
+	NULL
)	NULL
DOC	NULL
treatment	NULL
.	NULL

The	NULL
same	NULL
probe	NULL
was	NULL
used	NULL
as	NULL
a	NULL
competitor	NULL
in	NULL
the	NULL
IL-2-stimulated	NULL
lane	NULL
(	NULL
IL-2+	NULL
,	NULL
Comp+	NULL
)	NULL
.	NULL

S	NULL
phase	NULL
and	NULL
p130	NULL
complexes	NULL
,	NULL
and	NULL
free	NULL
E2F4	NULL
were	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Supershift	NULL
analysis	NULL
of	NULL
E2F	NULL
complexes	NULL
and	NULL
free	NULL
E2Fs	NULL
.	NULL

Antibodies	NULL
indicated	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reactions	NULL
10	NULL
min	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
.	NULL

Lysates	NULL
were	NULL
prepared	NULL
from	NULL
IL-2-starved	NULL
Kit	NULL
225	NULL
cells	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
,	NULL
cells	NULL
stimulated	NULL
with	NULL
IL-2	NULL
for	NULL
24	NULL
h	NULL
(	NULL
middle	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
cells	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
(	NULL
middle	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

Free	NULL
E2Fs	NULL
were	NULL
released	NULL
by	NULL
DOC	NULL
treatment	NULL
(	NULL
DOC	NULL
+	NULL
)	NULL
of	NULL
lysates	NULL
from	NULL
cells	NULL
stimulated	NULL
with	NULL
IL-2	NULL
for	NULL
24	NULL
h	NULL
(	NULL
right	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
by	NULL
Tax	NULL
for	NULL
72	NULL
h	NULL
(	NULL
right	NULL
lower	NULL
panel	NULL
)	NULL
2059	NULL
Oncogene	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
analysis	NULL
with	NULL
antibodies	NULL
for	NULL
pRb	NULL
and	NULL
p130	NULL
detected	NULL
two	NULL
close	NULL
but	NULL
distinct	NULL
bands	NULL
;	NULL
the	NULL
upper	NULL
and	NULL
lower	NULL
bands	NULL
represent	NULL
hyperphosphorylated	NULL
and	NULL
unphosphorylated	NULL
/hypophosphorylated	NULL
forms	NULL
,	NULL
respectively	NULL
.	NULL

Infection	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
increased	NULL
the	NULL
ratio	NULL
of	NULL
phosphorylated	NULL
forms	NULL
to	NULL
unphosphorylated	NULL
ones	NULL
of	NULL
both	NULL
Rb	NULL
family	NULL
members	NULL
similar	NULL
to	NULL
stimulation	NULL
with	NULL
IL-2	NULL
which	NULL
phosphorylated	NULL
the	NULL
molecules	NULL
more	NULL
efficiently	NULL
than	NULL
Tax	NULL
with	NULL
advanced	NULL
kinetics	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
considered	NULL
that	NULL
effect	NULL
of	NULL
Tax	NULL
appeared	NULL
only	NULL
in	NULL
a	NULL
half	NULL
of	NULL
the	NULL
population	NULL
of	NULL
cells	NULL
because	NULL
of	NULL
the	NULL
infection	NULL
efficiency	NULL
.	NULL

Similar	NULL
increases	NULL
in	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
were	NULL
seen	NULL
with	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
mutant	NULL
Taxd3	NULL
recombinant	NULL
virus	NULL
that	NULL
could	NULL
also	NULL
induce	NULL
E2F	NULL
activation	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Other	NULL
mutants	NULL
,	NULL
Taxd17/5	NULL
and	NULL
TaxM22	NULL
,	NULL
were	NULL
not	NULL
effective	NULL
.	NULL

Amounts	NULL
of	NULL
p107	NULL
increased	NULL
with	NULL
a	NULL
slight	NULL
shift	NULL
in	NULL
mobility	NULL
after	NULL
expression	NULL
of	NULL
either	NULL
Tax	NULL
or	NULL
Taxd3	NULL
like	NULL
stimulation	NULL
with	NULL
IL-2	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Tax	NULL
has	NULL
the	NULL
ability	NULL
to	NULL
induce	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
coincided	NULL
with	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
observations	NULL
,	NULL
we	NULL
speculated	NULL
that	NULL
Tax	NULL
induced	NULL
activation	NULL
of	NULL
G1	NULL
CDKs	NULL
.	NULL

Activation	NULL
of	NULL
G1	NULL
cyclin	NULL
dependent	NULL
kinases	NULL
by	NULL
Tax	NULL
D-type	NULL
CDKs	NULL
(	NULL
CDK4	NULL
and	NULL
CDK6	NULL
)	NULL
are	NULL
responsible	NULL
for	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
.	NULL

In	NULL
addition	NULL
cyclin	NULL
E	NULL
expressed	NULL
at	NULL
G1/S	NULL
boundary	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
through	NULL
activation	NULL
of	NULL
CDK2	NULL
.	NULL

We	NULL
thus	NULL
examined	NULL
whether	NULL
expression	NULL
of	NULL
Tax	NULL
induced	NULL
activation	NULL
of	NULL
CDK2	NULL
and	NULL
CDK4	NULL
in	NULL
IL-2-starved	NULL
Kit	NULL
225	NULL
cells	NULL
Cell	NULL
lysates	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
24	NULL
h	NULL
,	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
were	NULL
subjected	NULL
to	NULL
immunoprecipitation	NULL
with	NULL
antibodies	NULL
for	NULL
CDK2	NULL
and	NULL
CDK4	NULL
.	NULL

The	NULL
immunoprecipitates	NULL
were	NULL
examined	NULL
for	NULL
their	NULL
kinase	NULL
activities	NULL
using	NULL
GST-Rb	NULL
and	NULL
histone	NULL
H1	NULL
as	NULL
substrates	NULL
.	NULL

As	NULL
controls	NULL
,	NULL
cells	NULL
either	NULL
kept	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
were	NULL
used	NULL
.	NULL

Any	NULL
anti-CDK4	NULL
antibody-mediated	NULL
immunoprecipi-	NULL
tates	NULL
from	NULL
cells	NULL
24	NULL
h	NULL
post	NULL
infection	NULL
showed	NULL
the	NULL
same	NULL
background	NULL
levels	NULL
of	NULL
kinase	NULL
activities	NULL
as	NULL
that	NULL
from	NULL
IL-2-starved	NULL
cells	NULL
.	NULL

Further	NULL
culture	NULL
of	NULL
cells	NULL
for	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
induced	NULL
CDK4	NULL
kinase	NULL
activity	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

Similar	NULL
activation	NULL
was	NULL
seen	NULL
with	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
mutant	NULL
Taxd3	NULL
recombinant	NULL
virus	NULL
but	NULL
not	NULL
other	NULL
mutant	NULL
Tax	NULL
(	NULL
Taxd17/5	NULL
and	NULL
TaxM22	NULL
)	NULL
recombinant	NULL
viruses	NULL
.	NULL

Rb	NULL
kinase	NULL
activity	NULL
associated	NULL
with	NULL
anti-CDK6	NULL
antibody-mediated	NULL
immunoprecipitates	NULL
could	NULL
not	NULL
be	NULL
detected	NULL
under	NULL
similar	NULL
conditions	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Kinase	NULL
activity	NULL
associated	NULL
with	NULL
anti-CDK2-mediated	NULL
immunoprecipitates	NULL
from	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
Tax	NULL
and	NULL
mutant	NULL
Taxd3	NULL
recombinant	NULL
viruses	NULL
phosphorylated	NULL
GST-Rb	NULL
and	NULL
histone	NULL
H1	NULL
with	NULL
the	NULL
same	NULL
time	NULL
course	NULL
as	NULL
that	NULL
with	NULL
CDK4	NULL
.	NULL

CDK4	NULL
and	NULL
CDK2	NULL
were	NULL
activated	NULL
by	NULL
IL-2	NULL
stimulation	NULL
with	NULL
advanced	NULL
kinetics	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Tax	NULL
induces	NULL
the	NULL
activation	NULL
of	NULL
CDK4	NULL
and	NULL
CDK2	NULL
with	NULL
kinetics	NULL
coinciding	NULL
with	NULL
that	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
induced	NULL
by	NULL
Tax	NULL
.	NULL

Effect	NULL
of	NULL
Tax	NULL
on	NULL
CDK	NULL
inhibitors	NULL
CDK	NULL
inhibitors	NULL
are	NULL
regulatory	NULL
molecules	NULL
for	NULL
kinase	NULL
activity	NULL
of	NULL
CDK	NULL
complexes	NULL
.	NULL

Kit	NULL
225	NULL
cells	NULL
have	NULL
been	NULL
found	NULL
to	NULL
express	NULL
little	NULL
or	NULL
no	NULL
detectable	NULL
level	NULL
of	NULL
p16'*~	NULL
``	NULL
*	NULL
,	NULL
indicating	NULL
that	NULL
activation	NULL
of	NULL
G1	NULL
CDKs	NULL
by	NULL
Tax	NULL
is	NULL
independent	NULL
of	NULL
p16N**	NULL
(	NULL
Ohtani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

Thus	NULL
we	NULL
examined	NULL
whether	NULL
Tax	NULL
affected	NULL
the	NULL
expression	NULL
of	NULL
CDK	NULL
inhibitors	NULL
p15	NULL
``	NULL
,	NULL
p18	NULL
``	NULL
,	NULL
p21©	NULL
'	NULL
and	NULL
p27°®P	NULL
!	NULL

at	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

Tax	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
repress	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
p18	NULL
``	NULL
~**	NULL
``	NULL
gene	NULL
(	NULL
Suzuki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
hybridization	NULL
with	NULL
a	NULL
probe	NULL
specific	NULL
for	NULL
the	NULL
p18	NULL
``	NULL
gene	NULL
detected	NULL
three	NULL
distinct	NULL
bands	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

The	NULL
middle	NULL
band	NULL
appeared	NULL
after	NULL
introduction	NULL
of	NULL
Tax	NULL
and	NULL
increased	NULL
in	NULL
density	NULL
with	NULL
time	NULL
.	NULL

High	NULL
molecular	NULL
weight	NULL
species	NULL
of	NULL
mRNA	NULL
for	NULL
p18	NULL
``	NULL
also	NULL
increased	NULL
by	NULL
Tax	NULL
as	NULL
well	NULL
as	NULL
IL-2	NULL
.	NULL

These	NULL
results	NULL
clearly	NULL
demonstrate	NULL
that	NULL
Tax	NULL
rather	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
p18	NULL
``	NULL
at	NULL
transcriptional	NULL
level	NULL
.	NULL

No	NULL
significant	NULL
change	NULL
in	NULL
amount	NULL
of	NULL
p18	NULL
``	NULL
protein	NULL
was	NULL
seen	NULL
by	NULL
Tax	NULL
introduction	NULL
and	NULL
IL-2	NULL
treatment	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

pRb	NULL
p130	NULL
p10o7	NULL
i	NULL
Pa	NULL
it	NULL
R	NULL
a	NULL
hs	NULL
E	NULL
x	NULL
]	NULL
+	NULL
=	NULL
a	NULL
20+	NULL
ﬁg	NULL
+	NULL
5	NULL
8	NULL
s	NULL
&	NULL
4	NULL
gga	NULL
$	NULL
i	NULL
g	NULL
4	NULL
jig	NULL
s	NULL
g	NULL
i	NULL
pas	NULL
lj	NULL
$	NULL
o	NULL
I	NULL
=	NULL
06	NULL
A	NULL
#	NULL
E	NULL
#	NULL
1	NULL
<	NULL
1	NULL
0	NULL
E	NULL
E	NULL
2	NULL
2	NULL
o	NULL
i	NULL
<	NULL
o	NULL
¢	NULL
P	NULL
f	NULL
i*	NULL
Ts	NULL
.	NULL

bo	NULL
VB	NULL
W	NULL
14	NULL
bs	NULL
We	NULL
Wt	NULL
--	NULL
-	NULL
L	NULL
...	NULL
.ss	NULL
-	NULL
denies	NULL
-	NULL
Gomi	NULL
Figure	NULL
4	NULL
Phosphorylation	NULL
of	NULL
Rb	NULL
family	NULL
proteins	NULL
by	NULL
Tax	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
indicated	NULL
recombinant	NULL
adenoviruses	NULL
and	NULL
cells	NULL
left	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
as	NULL
in	NULL
Figure	NULL
1A	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
cells	NULL
starved	NULL
of	NULL
IL-2	NULL
for	NULL
48	NULL
h	NULL
(	NULL
0	NULL
h	NULL
in	NULL
figure	NULL
)	NULL
were	NULL
also	NULL
used	NULL
.	NULL

Western	NULL
blots	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
40	NULL
ug	NULL
of	NULL
sample	NULL
proteins	NULL
and	NULL
pRb	NULL
,	NULL
p130	NULL
and	NULL
p107	NULL
were	NULL
detected	NULL
with	NULL
corresponding	NULL
antibodies	NULL
Oncogene	NULL
'	NULL
E	NULL
o	NULL
Q	NULL
1	NULL
+	NULL
6	NULL
9	NULL
s	NULL
C	NULL
<	NULL
M	NULL
V	NULL
5	NULL
%	NULL
83	NULL
8	NULL
<	NULL
``	NULL
o	NULL
13	NULL
1	NULL
0	NULL
F	NULL
F	NULL
-	NULL
F	NULL
o	NULL
13	NULL
72	NULL
h	NULL
(	NULL
®	NULL
IP	NULL
:	NULL
anti-Cdk4	NULL
Substrate	NULL
:	NULL
GST-Rb	NULL
IL-2	NULL
+	NULL
Con	NULL
8	NULL
a	NULL
IP	NULL
:	NULL
anti-Cdk2	NULL
Substrate	NULL
:	NULL
GST-Rb	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
w	NULL
w	NULL
-	NULL
e	NULL
w	NULL
:	NULL
A	NULL
5:0	NULL
)	NULL
“	NULL
+	NULL
5:6	NULL
,	NULL
“	NULL
©	NULL
C	NULL
<	NULL
k	NULL
©	NULL
C	NULL
2	NULL
8883	NULL
1°	NULL
1°	NULL
iC	NULL
i=	NULL
o	NULL
=	NULL
1	NULL
0	NULL
°	NULL
iC	NULL
°	NULL
*	NULL
IP	NULL
:	NULL
anti-Cdk2	NULL
Substrate	NULL
:	NULL
histone	NULL
H1	NULL
Figure	NULL
5	NULL
Activation	NULL
of	NULL
CDK4	NULL
and	NULL
CDK2	NULL
by	NULL
Tax	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
indicated	NULL
recombinant	NULL
adenoviruses	NULL
and	NULL
cells	NULL
left	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
as	NULL
in	NULL
Figure	NULL
1A	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
cells	NULL
starved	NULL
of	NULL
IL-2	NULL
for	NULL
48	NULL
h	NULL
(	NULL
0	NULL
h	NULL
in	NULL
figure	NULL
)	NULL
were	NULL
also	NULL
used	NULL
.	NULL

Cell	NULL
lysates	NULL
(	NULL
100	NULL
ug	NULL
)	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-CDK4	NULL
or	NULL
anti-CDK2	NULL
antibodies	NULL
and	NULL
kinase	NULL
activities	NULL
of	NULL
the	NULL
immunoprecipitates	NULL
were	NULL
measured	NULL
by	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
using	NULL
GST-Rb	NULL
or	NULL
histone	NULL
H1	NULL
as	NULL
substrates	NULL
Tax	NULL
gradually	NULL
reduced	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
p19	NULL
``	NULL
gene	NULL
down	NULL
to	NULL
67	NULL
%	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

A	NULL
profound	NULL
decrease	NULL
in	NULL
protein	NULL
was	NULL
detected	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
,	NULL
presumably	NULL
indicating	NULL
that	NULL
Tax	NULL
may	NULL
affect	NULL
p19	NULL
``	NULL
~**	NULL
``	NULL
post-transcriptionally	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

No	NULL
appreciable	NULL
change	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
p15	NULL
``	NULL
N	NULL
``	NULL
**	NULL
``	NULL
was	NULL
seen	NULL
after	NULL
introduction	NULL
of	NULL
Tax	NULL
at	NULL
both	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
p27¢	NULL
``	NULL
'	NULL
gene	NULL
was	NULL
significantly	NULL
decreased	NULL
down	NULL
to	NULL
50	NULL
%	NULL
at	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
in	NULL
association	NULL
with	NULL
decrease	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
protein	NULL
.	NULL

These	NULL
decreases	NULL
were	NULL
seen	NULL
with	NULL
cells	NULL
either	NULL
treated	NULL
with	NULL
IL-2	NULL
or	NULL
infected	NULL
with	NULL
the	NULL
mutant	NULL
Taxd3	NULL
recombinant	NULL
virus	NULL
but	NULL
not	NULL
other	NULL
mutant	NULL
viruses	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
p21©	NULL
``	NULL
``	NULL
gene	NULL
was	NULL
not	NULL
expressed	NULL
in	NULL
quiescent	NULL
cells	NULL
and	NULL
induced	NULL
by	NULL
Tax	NULL
introduction	NULL
and	NULL
protein	NULL
levels	NULL
increased	NULL
with	NULL
time	NULL
after	NULL
infection	NULL
.	NULL

Tax-mediated	NULL
modulation	NULL
of	NULL
gene	NULL
expression	NULL
involved	NULL
in	NULL
CDK	NULL
activity	NULL
Modulation	NULL
of	NULL
cyclin	NULL
and	NULL
CDK	NULL
expression	NULL
by	NULL
Tax	NULL
could	NULL
be	NULL
one	NULL
of	NULL
mechanisms	NULL
by	NULL
which	NULL
CDK	NULL
activity	NULL
was	NULL
enhanced	NULL
in	NULL
Tax-expressing	NULL
cells	NULL
We	NULL
then	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
Tax	NULL
on	NULL
expression	NULL
of	NULL
cyclins	NULL
and	NULL
CDKs	NULL
by	NULL
Northern	NULL
and	NULL
Western	NULL
blot	NULL
analyses	NULL
.	NULL

Cyclin	NULL
D2	NULL
mRNA	NULL
increased	NULL
fourfold	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
,	NULL
even	NULL
when	NULL
only	NULL
a	NULL
marginal	NULL
progression	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
was	NULL
induced	NULL
by	NULL
Tax	NULL
(	NULL
Figure	NULL
7A	NULL
)	NULL
.	NULL

Elevation	NULL
of	NULL
cyclin	NULL
D2	NULL
mRNA	NULL
levels	NULL
by	NULL
Tax	NULL
remained	NULL
until	NULL
72	NULL
h.	NULL
Cyclin	NULL
D2	NULL
protein	NULL
was	NULL
detected	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
Tax	NULL
and	NULL
mutant	NULL
Taxd3	NULL
recombinant	NULL
viruses	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
Figure	NULL
7B	NULL
)	NULL
.	NULL

Except	NULL
for	NULL
these	NULL
two	NULL
points	NULL
,	NULL
little	NULL
,	NULL
if	NULL
any	NULL
,	NULL
or	NULL
no	NULL
expression	NULL
of	NULL
cyclin	NULL
D2	NULL
protein	NULL
was	NULL
seen	NULL
,	NULL
even	NULL
though	NULL
mRNA	NULL
for	NULL
cyclin	NULL
D2	NULL
was	NULL
detected	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Tax	NULL
induces	NULL
endogenous	NULL
cyclin	NULL
D2	NULL
through	NULL
activation	NULL
of	NULL
the	NULL
cyclin	NULL
D2	NULL
gene	NULL
expression	NULL
prior	NULL
to	NULL
progression	NULL
of	NULL
cell	NULL
cycle	NULL
by	NULL
Tax	NULL
.	NULL

Expression	NULL
of	NULL
cyclin	NULL
D3	NULL
was	NULL
not	NULL
significantly	NULL
affected	NULL
by	NULL
Tax	NULL
at	NULL
both	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

A	NULL
twofold	NULL
increase	NULL
in	NULL
cyclin	NULL
E	NULL
mRNA	NULL
was	NULL
observed	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
at	NULL
48	NULL
h	NULL
,	NULL
but	NULL
Western	NULL
blot	NULL
analysis	NULL
showed	NULL
no	NULL
significant	NULL
change	NULL
in	NULL
cyclin	NULL
E	NULL
protein	NULL
.	NULL

Quiescent	NULL
Kit	NULL
225	NULL
cells	NULL
showed	NULL
undetectable	NULL
or	NULL
background	NULL
level	NULL
of	NULL
mRNA	NULL
for	NULL
cyclin	NULL
A	NULL
.	NULL

Tax	NULL
clearly	NULL
induced	NULL
expression	NULL
of	NULL
mRNA	NULL
for	NULL
cyclin	NULL
A	NULL
at	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
,	NULL
and	NULL
the	NULL
induced	NULL
levels	NULL
of	NULL
the	NULL
expression	NULL
remained	NULL
until	NULL
72	NULL
h.	NULL
Levels	NULL
of	NULL
mRNA	NULL
for	NULL
CDK2	NULL
,	NULL
CDK4	NULL
and	NULL
CDK6	NULL
were	NULL
all	NULL
elevated	NULL
in	NULL
cells	NULL
with	NULL
wild	NULL
type	NULL
Tax	NULL
and	NULL
mutant	NULL
Taxd3	NULL
with	NULL
slightly	NULL
different	NULL
kinetics	NULL
.	NULL

cdk2	NULL
mRNA	NULL
levels	NULL
were	NULL
induced	NULL
three	NULL
and	NULL
eightfolds	NULL
at	NULL
48	NULL
h	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
,	NULL
respectively	NULL
.	NULL

cdk4	NULL
mRNA	NULL
similarly	NULL
increased	NULL
by	NULL
two	NULL
and	NULL
fourfolds	NULL
.	NULL

Twofold	NULL
increase	NULL
in	NULL
cdk6	NULL
mRNA	NULL
by	NULL
Tax	NULL
was	NULL
detected	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
and	NULL
was	NULL
kept	NULL
at	NULL
the	NULL
same	NULL
level	NULL
until	NULL
72	NULL
h.	NULL
Increase	NULL
in	NULL
CDK2	NULL
and	NULL
CDK4	NULL
proteins	NULL
was	NULL
also	NULL
detected	NULL
at	NULL
72	NULL
h	NULL
as	NULL
shown	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
and	NULL
increase	NULL
in	NULL
CDK6	NULL
protein	NULL
by	NULL
Tax	NULL
was	NULL
observed	NULL
at	NULL
24	NULL
h	NULL
through	NULL
72	NULL
h.	NULL
Kinetics	NULL
of	NULL
induction	NULL
of	NULL
cdc2	NULL
mRNA	NULL
by	NULL
Tax	NULL
were	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
cyclin	NULL
A	NULL
.	NULL

Many	NULL
of	NULL
the	NULL
changes	NULL
induced	NULL
by	NULL
Tax	NULL
were	NULL
also	NULL
induced	NULL
by	NULL
mutant	NULL
Taxd3	NULL
but	NULL
not	NULL
by	NULL
other	NULL
mutants	NULL
,	NULL
TaxM22	NULL
and	NULL
Taxd17/5	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
cdk6	NULL
,	NULL
indicating	NULL
that	NULL
ability	NULL
to	NULL
transactivate	NULL
the	NULL
NF-xB	NULL
pathway	NULL
is	NULL
important	NULL
for	NULL
modulation	NULL
of	NULL
expression	NULL
these	NULL
genes	NULL
by	NULL
Tax	NULL
.	NULL

TaxM22	NULL
induced	NULL
cdk6	NULL
expression	NULL
,	NULL
indicating	NULL
that	NULL
CREB	NULL
and/or	NULL
SRF	NULL
transcription	NULL
pathway	NULL
is	NULL
sufficient	NULL
for	NULL
induction	NULL
of	NULL
cdk6	NULL
.	NULL

Discussion	NULL
The	NULL
present	NULL
study	NULL
clearly	NULL
demonstrates	NULL
that	NULL
Tax	NULL
activates	NULL
G1	NULL
CDKs	NULL
,	NULL
which	NULL
are	NULL
shown	NULL
to	NULL
be	NULL
the	NULL
key	NULL
regulators	NULL
of	NULL
the	NULL
G1	NULL
to	NULL
S	NULL
phase	NULL
transition	NULL
.	NULL

The	NULL
activation	NULL
presumably	NULL
results	NULL
from	NULL
modulation	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
set	NULL
of	NULL
genes	NULL
for	NULL
cell	NULL
cycle	NULL
regulatory	NULL
molecules	NULL
.	NULL

Our	NULL
observations	NULL
underscore	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
transactivating	NULL
function	NULL
of	NULL
Tax	NULL
in	NULL
cell	NULL
growth	NULL
stimulation	NULL
in	NULL
that	NULL
not	NULL
only	NULL
inducing	NULL
growth	NULL
signaling	NULL
molecules	NULL
but	NULL
also	NULL
inducing	NULL
cell	NULL
cycle	NULL
regulatory	NULL
molecules	NULL
.	NULL

2061	NULL
Oncogene	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
2062	NULL
A	NULL
24	NULL
h	NULL
1	NULL
10+	NULL
=	NULL
”	NULL
§	NULL
»	NULL
gﬂquggﬁ	NULL
nl	NULL
a	NULL
1	NULL
1	NULL
0	NULL
°	NULL
£	NULL
°	NULL
£	NULL
=	NULL
!	NULL

p18-f	NULL
h	NULL
J	NULL
bj	NULL
Taxd17/5	NULL
IL-2	NULL
IL-2	NULL
+	NULL
Con	NULL
Tax	NULL
Taxd3	NULL
TaxM22	NULL
IL-2	NULL
p18	NULL
kel	NULL
wah	NULL
«	NULL
w	NULL
3	NULL
p21	NULL
1	NULL
|	NULL
p27	NULL
~	NULL
N	NULL
t	NULL
>	NULL
a	NULL
IL-2	NULL
+	NULL
Con	NULL
IL-2	NULL
+	NULL
48	NULL
h	NULL
72	NULL
h	NULL
3	NULL
E	NULL
o	NULL
8	NULL
E	NULL
o	NULL
$	NULL
a	NULL
o	NULL
0	NULL
E	NULL
¢	NULL
;	NULL
‘	NULL
+=	NULL
©	NULL
0	NULL
&	NULL
s	NULL
5	NULL
a	NULL
a	NULL
8	NULL
3	NULL
Y	NULL
o	NULL
5	NULL
3	NULL
8	NULL
5	NULL
o	NULL
F	NULL
E	NULL
FoF	NULL
1	NULL
1	NULL
0	NULL
-	NULL
-F	NULL
to	NULL
J	NULL
&	NULL
Co	NULL
ai	NULL
``	NULL
Taxd17/5	NULL
Taxd3	NULL
TaxM22	NULL
IL-2	NULL
IL-2	NULL
+	NULL
Con	NULL
Tax	NULL
Taxd17/5	NULL
Taxd3	NULL
TaxM22	NULL
Tax	NULL
~	NULL
Figure	NULL
6	NULL
Effects	NULL
of	NULL
Tax	NULL
on	NULL
expression	NULL
of	NULL
CDK	NULL
inhibitors	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
of	NULL
Tax	NULL
on	NULL
mRNA	NULL
expression	NULL
of	NULL
CDK	NULL
inhibitors	NULL
.	NULL

mRNAs	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
indicated	NULL
Tax	NULL
recombinant	NULL
adenoviruses	NULL
and	NULL
cells	NULL
left	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
as	NULL
in	NULL
Figure	NULL
1A	NULL
were	NULL
analysed	NULL
by	NULL
Northern	NULL
blotting	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
indicated	NULL
recombinant	NULL
adenoviruses	NULL
and	NULL
cells	NULL
left	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
as	NULL
in	NULL
Figure	NULL
1A	NULL
Initiation	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
adenoviruses	NULL
was	NULL
significantly	NULL
later	NULL
than	NULL
by	NULL
stimulation	NULL
with	NULL
IL-2	NULL
.	NULL

One	NULL
of	NULL
the	NULL
reasons	NULL
may	NULL
be	NULL
attributable	NULL
to	NULL
the	NULL
time	NULL
lag	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
Tax	NULL
from	NULL
the	NULL
recombinant	NULL
virus	NULL
as	NULL
shown	NULL
by	NULL
FACS	NULL
analysis	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Cells	NULL
require	NULL
48-72	NULL
h	NULL
after	NULL
infection	NULL
to	NULL
accumulate	NULL
enough	NULL
Tax	NULL
for	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Another	NULL
reason	NULL
is	NULL
that	NULL
only	NULL
half	NULL
population	NULL
of	NULL
the	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
virus	NULL
expressed	NULL
Tax	NULL
even	NULL
at	NULL
72	NULL
h.	NULL
Thus	NULL
the	NULL
effects	NULL
of	NULL
Tax	NULL
appeared	NULL
only	NULL
in	NULL
a	NULL
half	NULL
of	NULL
the	NULL
population	NULL
when	NULL
the	NULL
whole	NULL
population	NULL
of	NULL
cells	NULL
was	NULL
analysed	NULL
.	NULL

We	NULL
previously	NULL
demonstrated	NULL
that	NULL
Tax	NULL
activated	NULL
endogenous	NULL
E2F	NULL
,	NULL
resulting	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
Oncogene	NULL
promoters	NULL
of	NULL
a	NULL
series	NULL
of	NULL
genes	NULL
with	NULL
the	NULL
E2F	NULL
binding	NULL
sites	NULL
(	NULL
Ohtani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

The	NULL
present	NULL
study	NULL
further	NULL
demonstrates	NULL
that	NULL
Tax	NULL
releases	NULL
active	NULL
E2F4	NULL
from	NULL
the	NULL
complex	NULL
with	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
.	NULL

Tax	NULL
has	NULL
not	NULL
been	NULL
known	NULL
to	NULL
directly	NULL
associate	NULL
with	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
,	NULL
thus	NULL
it	NULL
is	NULL
less	NULL
likely	NULL
that	NULL
Tax	NULL
directly	NULL
modifies	NULL
the	NULL
pRb-E2F	NULL
complex	NULL
unlike	NULL
oncogene	NULL
products	NULL
of	NULL
DNA	NULL
tumor	NULL
viruses	NULL
such	NULL
as	NULL
the	NULL
T	NULL
antigen	NULL
of	NULL
SV40	NULL
and	NULL
Ela	NULL
of	NULL
adenovirus	NULL
(	NULL
Nevins	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
imply	NULL
that	NULL
the	NULL
generation	NULL
of	NULL
active	NULL
E2F4	NULL
is	NULL
a	NULL
result	NULL
of	NULL
indirect	NULL
effects	NULL
of	NULL
Tax	NULL
,	NULL
presumably	NULL
due	NULL
to	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
,	NULL
in	NULL
particular	NULL
p130	NULL
.	NULL

Northern	NULL
and	NULL
Western	NULL
blot	NULL
analyses	NULL
indicated	NULL
that	NULL
expression	NULL
of	NULL
E2F1	NULL
was	NULL
enhanced	NULL
by	NULL
Tax	NULL
at	NULL
mRNA	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
C.	NULL
)	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
2063	NULL
A	NULL
24	NULL
h	NULL
48	NULL
h	NULL
72	NULL
h	NULL
19	NULL
s	NULL
B	NULL
l	NULL
a	NULL
N	NULL
C	NULL
m	NULL
a	NULL
N	NULL
a	NULL
a	NULL
-	NULL
a	NULL
o	NULL
a	NULL
-	NULL
a	NULL
®	NULL
10+	NULL
=-	NULL
a	NULL
64	NULL
#	NULL
5x	NULL
3	NULL
$	NULL
%	NULL
a	NULL
4	NULL
og	NULL
x	NULL
3	NULL
$	NULL
&	NULL
a	NULL
a	NULL
g	NULL
y	NULL
$	NULL
$	NULL
3	NULL
s	NULL
1	NULL
1	NULL
0	NULL
°	NULL
E	NULL
°	NULL
E	NULL
1	NULL
1	NULL
0	NULL
C	NULL
°	NULL
E	NULL
E	NULL
1	NULL
1	NULL
0	NULL
°	NULL
E	NULL
E	NULL
®	NULL
samummes-	NULL
-	NULL
sssag-as	NULL
-	NULL
RiCRR	NULL
»	NULL
=	NULL
B	NULL
24	NULL
h	NULL
48	NULL
h	NULL
72	NULL
h	NULL
iC	NULL
hs	NULL
ou	NULL
E	NULL
a	NULL
<	NULL
E	NULL
»	NULL
§	NULL
0	NULL
7	NULL
E	NULL
a	NULL
§	NULL
0	NULL
7	NULL
Eo	NULL
§	NULL
)	NULL
F	NULL
=	NULL
a	NULL
-	NULL
+	NULL
6	NULL
+	NULL
t	NULL
t	NULL
3	NULL
w	NULL
a	NULL
o	NULL
a	NULL
a	NULL
5	NULL
E	NULL
R	NULL
E	NULL
A	NULL
&	NULL
&	NULL
1	NULL
a	NULL
0	NULL
F	NULL
A	NULL
F	NULL
1°	NULL
&	NULL
&	NULL
1	NULL
1	NULL
o	NULL
For	NULL
e	NULL
f	NULL
Z	NULL
&	NULL
t	NULL
a	NULL
a	NULL
``	NULL
Cyc	NULL
D2	NULL
Cyc	NULL
D3	NULL
O	NULL
a	NULL
.	NULL

[	NULL
x3	NULL
O	NULL
‘	NULL
x	NULL
pS	NULL
Cyc	NULL
E	NULL
Cdk4	NULL
Cdk6	NULL
Figure	NULL
7	NULL
Effects	NULL
of	NULL
Tax	NULL
on	NULL
expression	NULL
of	NULL
cyclins	NULL
and	NULL
CDKs	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
indicated	NULL
recombinant	NULL
adenoviruses	NULL
and	NULL
cells	NULL
left	NULL
IL-2-starved	NULL
or	NULL
restimulated	NULL
with	NULL
IL-2	NULL
as	NULL
in	NULL
Figure	NULL
1A	NULL
.	NULL

Western	NULL
blots	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
40	NULL
ug	NULL
of	NULL
sample	NULL
proteins	NULL
.	NULL

Cell	NULL
lysates	NULL
from	NULL
MT-2	NULL
and	NULL
MOLT-4	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
for	NULL
cyclin	NULL
D2	NULL
and	NULL
cyclin	NULL
D3	NULL
,	NULL
respectively	NULL
.	NULL

Cyclin	NULL
D2	NULL
molecules	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

Although	NULL
the	NULL
activity	NULL
of	NULL
E2F1	NULL
to	NULL
shift	NULL
assay	NULL
,	NULL
it	NULL
may	NULL
contribute	NULL
to	NULL
activation	NULL
of	NULL
bind	NULL
to	NULL
the	NULL
DNA	NULL
element	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
our	NULL
gel	NULL
_	NULL
endogenous	NULL
E2F	NULL
by	NULL
Tax	NULL
.	NULL

Oncogene	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
2064	NULL
Kinase	NULL
activities	NULL
responsible	NULL
for	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
were	NULL
monitored	NULL
in	NULL
cells	NULL
after	NULL
Tax	NULL
expression	NULL
.	NULL

In	NULL
vitro	NULL
kinase	NULL
assay	NULL
showed	NULL
that	NULL
Tax	NULL
induced	NULL
activation	NULL
of	NULL
CDK4	NULL
and	NULL
CDK2	NULL
in	NULL
quiescent	NULL
Kit	NULL
225	NULL
.	NULL

The	NULL
same	NULL
assay	NULL
failed	NULL
to	NULL
detect	NULL
kinase	NULL
activity	NULL
in	NULL
the	NULL
immunoprecipitates	NULL
mediated	NULL
by	NULL
anti-cyclin	NULL
D2	NULL
and	NULL
anti-cyclin	NULL
D3	NULL
antibodies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
thus	NULL
it	NULL
is	NULL
not	NULL
known	NULL
which	NULL
cyclin	NULL
is	NULL
involved	NULL
in	NULL
Tax-induced	NULL
activation	NULL
of	NULL
CDK4	NULL
.	NULL

We	NULL
demonstrated	NULL
that	NULL
Tax	NULL
trans-activated	NULL
the	NULL
cyclin	NULL
D2	NULL
gene	NULL
,	NULL
but	NULL
not	NULL
cyclin	NULL
D3	NULL
gene	NULL
,	NULL
resulting	NULL
in	NULL
elevation	NULL
of	NULL
the	NULL
cyclin	NULL
D2	NULL
protein	NULL
level	NULL
.	NULL

It	NULL
may	NULL
be	NULL
possible	NULL
that	NULL
cyclin	NULL
D2	NULL
is	NULL
involved	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
activation	NULL
of	NULL
CDK4	NULL
in	NULL
Tax-expressing	NULL
cells	NULL
.	NULL

cdk4	NULL
was	NULL
tanscriptionally	NULL
up-regulated	NULL
by	NULL
Tax	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
likely	NULL
that	NULL
there	NULL
could	NULL
be	NULL
a	NULL
close	NULL
link	NULL
between	NULL
Tax-induced	NULL
increases	NULL
in	NULL
amount	NULL
and	NULL
activity	NULL
of	NULL
CDK4	NULL
.	NULL

Tax	NULL
profoundly	NULL
decreased	NULL
the	NULL
amount	NULL
of	NULL
p19	NULL
``	NULL
~	NULL
``	NULL
*	NULL
``	NULL
protein	NULL
,	NULL
which	NULL
could	NULL
also	NULL
contribute	NULL
to	NULL
activation	NULL
of	NULL
CDK4	NULL
.	NULL

The	NULL
level	NULL
of	NULL
cyclin	NULL
E	NULL
,	NULL
which	NULL
binds	NULL
and	NULL
regulates	NULL
CDK2	NULL
,	NULL
did	NULL
not	NULL
fluctuate	NULL
between	NULL
quiescent	NULL
and	NULL
Tax-expressing	NULL
cells	NULL
,	NULL
although	NULL
its	NULL
mRNA	NULL
level	NULL
was	NULL
induced	NULL
twofolds	NULL
by	NULL
Tax	NULL
.	NULL

Tax	NULL
thus	NULL
seemed	NULL
to	NULL
induce	NULL
activity	NULL
of	NULL
CDK2	NULL
in	NULL
a	NULL
cyclin	NULL
E-independent	NULL
manner	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
it	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
CDK2	NULL
was	NULL
elevated	NULL
by	NULL
Tax	NULL
at	NULL
both	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

Tax-dependent	NULL
increase	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
CDK2	NULL
may	NULL
be	NULL
the	NULL
main	NULL
cause	NULL
of	NULL
induction	NULL
of	NULL
CDK2	NULL
activity	NULL
.	NULL

Another	NULL
possibility	NULL
is	NULL
sequestration	NULL
of	NULL
p27	NULL
``	NULL
by	NULL
cyclin	NULL
D2	NULL
and	NULL
CDK4	NULL
increased	NULL
by	NULL
Tax	NULL
,	NULL
leading	NULL
to	NULL
activation	NULL
of	NULL
the	NULL
cyclin	NULL
E/CDK2	NULL
complex	NULL
that	NULL
may	NULL
phosphorylate	NULL
p27¢	NULL
``	NULL
.	NULL

Consequently	NULL
level	NULL
of	NULL
p27	NULL
``	NULL
is	NULL
reduced	NULL
by	NULL
ubiquitin-mediated	NULL
degradation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
induction	NULL
of	NULL
cyclin	NULL
A	NULL
by	NULL
Tax	NULL
may	NULL
also	NULL
contribute	NULL
to	NULL
activation	NULL
of	NULL
CDK2	NULL
.	NULL

The	NULL
integration	NULL
of	NULL
these	NULL
modulations	NULL
induced	NULL
by	NULL
Tax	NULL
probably	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
CDKs	NULL
.	NULL

Kinase	NULL
activities	NULL
of	NULL
CDK4	NULL
and	NULL
CDK2	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
Tax	NULL
recombinant	NULL
virus	NULL
were	NULL
activated	NULL
at	NULL
48	NULL
h	NULL
and	NULL
were	NULL
most	NULL
evident	NULL
at	NULL
72	NULL
h	NULL
in	NULL
contrast	NULL
to	NULL
those	NULL
induced	NULL
by	NULL
IL-2	NULL
which	NULL
were	NULL
most	NULL
evident	NULL
at	NULL
24	NULL
h.	NULL
All	NULL
of	NULL
the	NULL
events	NULL
downstream	NULL
of	NULL
activation	NULL
of	NULL
G1	NULL
CDKs	NULL
such	NULL
as	NULL
phosphorylation	NULL
of	NULL
Rb	NULL
family	NULL
proteins	NULL
,	NULL
down	NULL
regulation	NULL
of	NULL
p27¢	NULL
``	NULL
``	NULL
and	NULL
induction	NULL
of	NULL
free	NULL
E2F4	NULL
were	NULL
induced	NULL
at	NULL
24	NULL
h	NULL
by	NULL
stimulation	NULL
with	NULL
IL-2	NULL
and	NULL
at	NULL
72	NULL
h	NULL
by	NULL
Tax	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
Tax-induced	NULL
cell	NULL
cycle	NULL
progression	NULL
seems	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
activation	NULL
of	NULL
G1	NULL
CDKs	NULL
.	NULL

Unlike	NULL
other	NULL
cell	NULL
cycle	NULL
regulatory	NULL
events	NULL
which	NULL
are	NULL
activated	NULL
at	NULL
48	NULL
h	NULL
through	NULL
72	NULL
h	NULL
by	NULL
Tax	NULL
,	NULL
the	NULL
cyclin	NULL
D2	NULL
,	NULL
E2F1	NULL
and	NULL
cdk6	NULL
genes	NULL
were	NULL
activated	NULL
by	NULL
Tax	NULL
as	NULL
early	NULL
as	NULL
24	NULL
h	NULL
when	NULL
activation	NULL
of	NULL
CDKs	NULL
and	NULL
progression	NULL
to	NULL
S	NULL
and	NULL
G2/M	NULL
phases	NULL
were	NULL
not	NULL
yet	NULL
observed	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
three	NULL
genes	NULL
is	NULL
the	NULL
primary	NULL
effect	NULL
mediated	NULL
by	NULL
Tax	NULL
.	NULL

It	NULL
may	NULL
be	NULL
expected	NULL
that	NULL
Tax	NULL
induces	NULL
the	NULL
same	NULL
group	NULL
of	NULL
genes	NULL
to	NULL
the	NULL
same	NULL
extent	NULL
as	NULL
stimulation	NULL
with	NULL
IL-2	NULL
.	NULL

It	NULL
is	NULL
intriguing	NULL
to	NULL
note	NULL
that	NULL
,	NULL
there	NULL
are	NULL
differences	NULL
in	NULL
induction	NULL
of	NULL
cell	NULL
cycle	NULL
regulatory	NULL
genes	NULL
between	NULL
Tax	NULL
and	NULL
IL-2	NULL
.	NULL

Tax	NULL
stimulated	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
cyclin	NULL
E	NULL
,	NULL
p21°	NULL
``	NULL
``	NULL
and	NULL
cdk6	NULL
genes	NULL
that	NULL
were	NULL
not	NULL
significantly	NULL
Oncogene	NULL
affected	NULL
by	NULL
IL-2	NULL
.	NULL

Induction	NULL
of	NULL
E2F1	NULL
,	NULL
cdk2	NULL
and	NULL
edk4	NULL
genes	NULL
by	NULL
Tax	NULL
was	NULL
much	NULL
stronger	NULL
than	NULL
that	NULL
with	NULL
stimulation	NULL
with	NULL
IL-2	NULL
.	NULL

Moreover	NULL
,	NULL
IL-2	NULL
induced	NULL
the	NULL
upper	NULL
band	NULL
of	NULL
pl8	NULL
``	NULL
~**	NULL
,	NULL
whereas	NULL
Tax	NULL
induced	NULL
the	NULL
middle	NULL
band	NULL
.	NULL

These	NULL
results	NULL
imply	NULL
that	NULL
Tax	NULL
does	NULL
have	NULL
the	NULL
distinct	NULL
effects	NULL
on	NULL
cell	NULL
cycle	NULL
regulatory	NULL
genes	NULL
from	NULL
IL-2	NULL
,	NULL
indicating	NULL
that	NULL
Tax	NULL
does	NULL
not	NULL
simply	NULL
stimulate	NULL
growth	NULL
signaling	NULL
pathway	NULL
induced	NULL
by	NULL
IL-2	NULL
.	NULL

These	NULL
results	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
Tax	NULL
directly	NULL
mediates	NULL
induction	NULL
of	NULL
cell	NULL
cycle	NULL
regulatory	NULL
genes	NULL
rather	NULL
than	NULL
through	NULL
growth	NULL
signaling	NULL
pathway	NULL
.	NULL

Tax	NULL
greatly	NULL
induced	NULL
expression	NULL
of	NULL
at	NULL
both	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

High	NULL
expression	NULL
of	NULL
p21©®	NULL
``	NULL
``	NULL
mRNA	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
HTLV-I	NULL
transformed	NULL
cell	NULL
lines	NULL
(	NULL
Akagi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
induction	NULL
of	NULL
p21©	NULL
``	NULL
``	NULL
by	NULL
Tax	NULL
is	NULL
not	NULL
specific	NULL
to	NULL
Kit	NULL
225	NULL
cells	NULL
.	NULL

The	NULL
biological	NULL
significance	NULL
of	NULL
induction	NULL
of	NULL
p21°	NULL
``	NULL
``	NULL
by	NULL
Tax	NULL
is	NULL
not	NULL
known	NULL
at	NULL
present	NULL
.	NULL

p21°	NULL
»	NULL
``	NULL
may	NULL
facilitate	NULL
assembly	NULL
of	NULL
cyclin	NULL
D2	NULL
and	NULL
cyclin	NULL
D3	NULL
with	NULL
CDK4	NULL
and	NULL
CDK6	NULL
(	NULL
LaBaer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
,	NULL
contributing	NULL
in	NULL
activation	NULL
of	NULL
D-type	NULL
CDKs	NULL
.	NULL

Further	NULL
studies	NULL
are	NULL
needed	NULL
for	NULL
elucidation	NULL
of	NULL
role	NULL
(	NULL
s	NULL
)	NULL
of	NULL
p21°	NULL
``	NULL
``	NULL
induced	NULL
by	NULL
Tax	NULL
.	NULL

One	NULL
of	NULL
the	NULL
striking	NULL
results	NULL
in	NULL
the	NULL
present	NULL
study	NULL
is	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
activate	NULL
the	NULL
NF-xB	NULL
pathway	NULL
is	NULL
closely	NULL
associated	NULL
with	NULL
activation	NULL
of	NULL
a	NULL
set	NULL
of	NULL
endogenous	NULL
cell	NULL
cycle	NULL
regulatory	NULL
genes	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
our	NULL
previous	NULL
study	NULL
(	NULL
Ohtani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
,	NULL
exogenous	NULL
introduction	NULL
of	NULL
active	NULL
NF-xB	NULL
complex	NULL
is	NULL
not	NULL
effective	NULL
in	NULL
activation	NULL
of	NULL
E2F	NULL
.	NULL

Tax	NULL
may	NULL
activate	NULL
yet	NULL
unidentified	NULL
pathways	NULL
that	NULL
are	NULL
also	NULL
necessary	NULL
for	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

The	NULL
speculation	NULL
may	NULL
be	NULL
enforced	NULL
by	NULL
our	NULL
previous	NULL
observation	NULL
that	NULL
Tax	NULL
expressed	NULL
in	NULL
rat	NULL
fibroblast	NULL
trans-activates	NULL
the	NULL
NF-xB	NULL
sites	NULL
but	NULL
does	NULL
not	NULL
activate	NULL
E2F	NULL
(	NULL
Ohtani	NULL
et	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

As	NULL
a	NULL
consequence	NULL
of	NULL
activation	NULL
of	NULL
G1	NULL
CDKs	NULL
by	NULL
Tax	NULL
,	NULL
phosphorylation	NULL
of	NULL
the	NULL
Rb	NULL
family	NULL
members	NULL
was	NULL
induced	NULL
as	NULL
shown	NULL
by	NULL
Western	NULL
blot	NULL
analyses	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
phosphorylation	NULL
of	NULL
p130	NULL
,	NULL
the	NULL
p130/	NULL
E2F4	NULL
complex	NULL
disappeared	NULL
and	NULL
free	NULL
E2F4	NULL
binding	NULL
activity	NULL
and	NULL
the	NULL
S	NULL
phase	NULL
complex	NULL
were	NULL
induced	NULL
in	NULL
Tax	NULL
expressing	NULL
cells	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

Recently	NULL
a	NULL
murine	NULL
pro-B	NULL
cell	NULL
line	NULL
,	NULL
Ba/F3	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
p130	NULL
as	NULL
a	NULL
regulator	NULL
of	NULL
cell	NULL
growth	NULL
inhibition	NULL
rather	NULL
than	NULL
pRb	NULL
(	NULL
Hoshikawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
growth	NULL
inhibitory	NULL
effect	NULL
of	NULL
p130	NULL
was	NULL
abrogated	NULL
by	NULL
expression	NULL
of	NULL
E2F4	NULL
.	NULL

Thus	NULL
,	NULL
p130	NULL
and	NULL
E2F4	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
major	NULL
determinants	NULL
of	NULL
cell	NULL
growth	NULL
of	NULL
lymphoid	NULL
lineage	NULL
.	NULL

Much	NULL
knowledge	NULL
concerning	NULL
regulation	NULL
of	NULL
Rb/E2F	NULL
complex	NULL
has	NULL
been	NULL
obtained	NULL
by	NULL
investigations	NULL
with	NULL
fibroblast	NULL
cells	NULL
(	NULL
Dyson	NULL
,	NULL
1998	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
have	NULL
revealed	NULL
that	NULL
a	NULL
shift	NULL
from	NULL
the	NULL
p130/E2F	NULL
complex	NULL
at	NULL
GO	NULL
phase	NULL
to	NULL
p107/E2F	NULL
complex	NULL
at	NULL
S	NULL
phase	NULL
is	NULL
observed	NULL
in	NULL
fibroblasts	NULL
.	NULL

In	NULL
Kit	NULL
225	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
this	NULL
shift	NULL
is	NULL
not	NULL
dramatic	NULL
as	NULL
in	NULL
fibroblasts	NULL
and	NULL
the	NULL
p130/E2F	NULL
complex	NULL
remains	NULL
at	NULL
S	NULL
phase	NULL
.	NULL

The	NULL
difference	NULL
may	NULL
reflect	NULL
differential	NULL
usage	NULL
of	NULL
Rb	NULL
family	NULL
members	NULL
in	NULL
different	NULL
tissues	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
transactivating	NULL
ability	NULL
of	NULL
Tax	NULL
is	NULL
important	NULL
in	NULL
Tax-induced	NULL
cell	NULL
cycle	NULL
promotion	NULL
with	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
group	NULL
of	NULL
cell	NULL
cycle	NULL
regulatory	NULL
genes	NULL
as	NULL
new	NULL
targets	NULL
of	NULL
Tax	NULL
.	NULL

Elucidation	NULL
of	NULL
yet	NULL
unknown	NULL
targets	NULL
of	NULL
Tax-mediated	NULL
trans-activation	NULL
should	NULL
provide	NULL
further	NULL
insights	NULL
into	NULL
understanding	NULL
cell	NULL
growth	NULL
promotion	NULL
and	NULL
eventually	NULL
leukemogenesis	NULL
induced	NULL
by	NULL
Tax	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cell	NULL
culture	NULL
IL-2-dependent	NULL
human	NULL
T-cell	NULL
line	NULL
Kit	NULL
225	NULL
(	NULL
Hori	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
and	NULL
0.5	NULL
nM	NULL
IL-2	NULL
(	NULL
Ajinomoto	NULL
,	NULL
Yokohama	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

HTLV-I	NULL
infected	NULL
human	NULL
T-cell	NULL
line	NULL
MT-2	NULL
(	NULL
Miyoshi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
and	NULL
HTLV-I	NULL
unrelated	NULL
MOLT-4	NULL
(	NULL
Minowada	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1972	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Human	NULL
kidney	NULL
epithelial	NULL
cell	NULL
line	NULL
293	NULL
(	NULL
Graham	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
)	NULL
was	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Infection	NULL
with	NULL
recombinant	NULL
adenoviruses	NULL
The	NULL
recombinant	NULL
adenovirus	NULL
for	NULL
expression	NULL
of	NULL
Tax	NULL
(	NULL
Ax-CAIY-Tax	NULL
)	NULL
and	NULL
its	NULL
mutants	NULL
Taxd3	NULL
(	NULL
AxCAIY-Taxd3	NULL
)	NULL
,	NULL
Taxd17/5	NULL
(	NULL
AxCAIY-Taxd17/5	NULL
)	NULL
and	NULL
TaxM22	NULL
(	NULL
AxCAIY-TaxM22	NULL
)	NULL
,	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
M	NULL
Yoshida	NULL
and	NULL
described	NULL
previously	NULL
(	NULL
Hirai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Ohtani	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

Taxd3	NULL
,	NULL
TaxM22	NULL
and	NULL
Taxd17/5	NULL
have	NULL
defect	NULL
in	NULL
activation	NULL
of	NULL
CREB	NULL
,	NULL
NF-xB	NULL
and	NULL
all	NULL
of	NULL
the	NULL
transcription	NULL
pathways	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
control	NULL
virus	NULL
,	NULL
Ad-Con	NULL
,	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
Schwarz	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

For	NULL
all	NULL
assays	NULL
,	NULL
Kit	NULL
225	NULL
cells	NULL
were	NULL
starved	NULL
of	NULL
IL-2	NULL
for	NULL
48	NULL
h	NULL
and	NULL
infected	NULL
with	NULL
the	NULL
recombinant	NULL
viruses	NULL
at	NULL
multiples	NULL
of	NULL
100	NULL
plaque	NULL
forming	NULL
units/cell	NULL
at	NULL
10	NULL
``	NULL
cells/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Cells	NULL
were	NULL
further	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
for	NULL
24	NULL
,	NULL
48	NULL
and	NULL
72	NULL
h	NULL
and	NULL
harvested	NULL
for	NULL
analyses	NULL
.	NULL

Mock	NULL
infected	NULL
cells	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
IL-2	NULL
were	NULL
used	NULL
as	NULL
negative	NULL
and	NULL
positive	NULL
controls	NULL
,	NULL
respectively	NULL
.	NULL

Tax	NULL
expression	NULL
and	NULL
DNA	NULL
content	NULL
analysis	NULL
Tax	NULL
was	NULL
stained	NULL
with	NULL
an	NULL
anti-Tax	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Lt-4	NULL
)	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
and	NULL
DNA	NULL
was	NULL
stained	NULL
with	NULL
propidium	NULL
iodide	NULL
.	NULL

Cells	NULL
were	NULL
examined	NULL
by	NULL
FACS	NULL
analysis	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Ohtani	NULL
er	NULL
al	NULL
.	NULL

,	NULL
2000	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
kinase	NULL
assay	NULL
Kinase	NULL
assays	NULL
with	NULL
pRb	NULL
and	NULL
histone	NULL
H1	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
with	NULL
minor	NULL
modifications	NULL
(	NULL
DeGregori	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
at	NULL
10	NULL
``	NULL
cells/ml	NULL
in	NULL
1	NULL
x	NULL
lysis	NULL
buffer	NULL
[	NULL
50	NULL
mM	NULL
N-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
piperazine-N'-	NULL
(	NULL
2-ethanesulfonic	NULL
acid	NULL
)	NULL
(	NULL
HEPES	NULL
)	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
150	NULL
mm	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
ethylenediaminetetraacetic	NULL
acid	NULL
(	NULL
EDTA	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
ethy-lene	NULL
_-	NULL
glycol-bis	NULL
(	NULL
#	NULL
-aminoethyl	NULL
_	NULL
ether	NULL
)	NULL
-N	NULL
,	NULL
N	NULL
,	NULL
N	NULL
'	NULL
,	NULL
N'-tetraacetic	NULL
acid	NULL
(	NULL
EGTA	NULL
)	NULL
,	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
10	NULL
mM	NULL
$	NULL
-glycerophosphate	NULL
,	NULL
1	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
0.1	NULL
mM	NULL
_	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
0.1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
5	NULL
ug/ml	NULL
aprotinin	NULL
and	NULL
1	NULL
ug/ml	NULL
pepstatin	NULL
AJ	NULL
and	NULL
were	NULL
frozen	NULL
in	NULL
liquid	NULL
nitrogen	NULL
.	NULL

Cells	NULL
were	NULL
thawed	NULL
,	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
microcentrifuged	NULL
for	NULL
10	NULL
min	NULL
at	NULL
13	NULL
000	NULL
r.p.m	NULL
.	NULL

Protein	NULL
concentrations	NULL
of	NULL
cell	NULL
lysates	NULL
were	NULL
measured	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
.	NULL

For	NULL
kinase	NULL
assays	NULL
,	NULL
cell	NULL
lysates	NULL
(	NULL
400	NULL
ug	NULL
for	NULL
pRb	NULL
and	NULL
100	NULL
ug	NULL
for	NULL
histone	NULL
H1	NULL
)	NULL
were	NULL
precleared	NULL
with	NULL
20	NULL
ul	NULL
of	NULL
50	NULL
%	NULL
protein	NULL
G-sepharose	NULL
beads	NULL
for	NULL
1	NULL
h.	NULL
Antibodies	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
against	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
CDK2	NULL
(	NULL
sc-163-G	NULL
)	NULL
,	NULL
CDK4	NULL
(	NULL
sc-601-G	NULL
)	NULL
or	NULL
CDK6	NULL
(	NULL
se-177-G	NULL
)	NULL
which	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
were	NULL
added	NULL
to	NULL
the	NULL
clarified	NULL
lysates	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
on	NULL
ice	NULL
,	NULL
followed	NULL
by	NULL
addition	NULL
of	NULL
10	NULL
ul	NULL
of	NULL
50	NULL
%	NULL
protein	NULL
G-sepharose	NULL
beads	NULL
and	NULL
incubation	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4°C	NULL
with	NULL
rocking	NULL
.	NULL

Immune	NULL
complexes	NULL
on	NULL
the	NULL
beads	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
1	NULL
x	NULL
lysis	NULL
buffer	NULL
and	NULL
twice	NULL
with	NULL
kinase	NULL
buffer	NULL
[	NULL
50	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
10	NULL
mm	NULL
MgCl	NULL
»	NULL
and	NULL
1mm	NULL
DTT	NULL
]	NULL
.	NULL

The	NULL
beads	NULL
containing	NULL
the	NULL
immune	NULL
complexes	NULL
were	NULL
then	NULL
suspended	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
kinase	NULL
buffer	NULL
either	NULL
containing	NULL
5	NULL
ug	NULL
of	NULL
GST-Rb	NULL
(	NULL
Ewen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
2.5	NULL
mM	NULL
EGTA	NULL
,	NULL
10	NULL
mm	NULL
B-glyceropho-sphate	NULL
,	NULL
0.1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
1	NULL
mM	NULL
NaF	NULL
,	NULL
20	NULL
mM	NULL
ATP	NULL
and	NULL
5	NULL
uCi	NULL
of	NULL
[	NULL
y-P	NULL
]	NULL
JATP	NULL
or	NULL
containing	NULL
5	NULL
ug	NULL
of	NULL
histone	NULL
H1	NULL
,	NULL
1	NULL
mm	NULL
ATP	NULL
and	NULL
5	NULL
uCi	NULL
of	NULL
[	NULL
y-P	NULL
]	NULL
JATP	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
30°C	NULL
with	NULL
occasional	NULL
mixing	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
addition	NULL
of	NULL
50	NULL
ul	NULL
of	NULL
2x	NULL
SDS	NULL
sample	NULL
buffer	NULL
and	NULL
then	NULL
the	NULL
samples	NULL
were	NULL
boiled	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Samples	NULL
(	NULL
30	NULL
wl	NULL
)	NULL
were	NULL
electrophoresed	NULL
through	NULL
either	NULL
a	NULL
12	NULL
or	NULL
8	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
an	NULL
imaging	NULL
plate	NULL
20408	NULL
(	NULL
Fuji	NULL
Film	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
analysis	NULL
with	NULL
an	NULL
image	NULL
analyser	NULL
BAS	NULL
1500	NULL
(	NULL
Fuji	NULL
Film	NULL
)	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
assay	NULL
Preparation	NULL
of	NULL
whole	NULL
cell	NULL
extract	NULL
and	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Ikeda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
typical	NULL
E2F	NULL
site	NULL
from	NULL
the	NULL
DHFR	NULL
promoter	NULL
was	NULL
used	NULL
for	NULL
a	NULL
probe	NULL
and	NULL
a	NULL
competitor	NULL
at	NULL
100-fold	NULL
molar	NULL
excess	NULL
.	NULL

For	NULL
supershift	NULL
assays	NULL
,	NULL
reaction	NULL
mixtures	NULL
without	NULL
radio-labeled	NULL
probe	NULL
were	NULL
preincubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
indicated	NULL
antibodies	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
radio-labeled	NULL
probe	NULL
was	NULL
then	NULL
added	NULL
and	NULL
further	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Antibodies	NULL
against	NULL
p130	NULL
(	NULL
se-317X	NULL
)	NULL
,	NULL
p107	NULL
(	NULL
se-250	NULL
%	NULL
)	NULL
,	NULL
cyclin	NULL
A	NULL
(	NULL
se-751	NULL
)	NULL
,	NULL
CDK2	NULL
(	NULL
se-163-G	NULL
)	NULL
,	NULL
E2F1	NULL
(	NULL
sc-251X	NULL
)	NULL
,	NULL
E2F2	NULL
(	NULL
sc-633X	NULL
)	NULL
,	NULL
E2F3	NULL
(	NULL
sc-878X	NULL
%	NULL
)	NULL
and	NULL
E2F4	NULL
(	NULL
sc-512X	NULL
)	NULL
were	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

C36	NULL
monoclonal	NULL
antibody	NULL
against	NULL
pRb	NULL
(	NULL
14031A	NULL
)	NULL
was	NULL
from	NULL
Pharmingen	NULL
.	NULL

Northern	NULL
(	NULL
RNA	NULL
)	NULL
blot	NULL
assay	NULL
Total	NULL
RNA	NULL
extraction	NULL
and	NULL
polyA	NULL
RNA	NULL
purification	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
Isogen	NULL
(	NULL
Nippon	NULL
Gene	NULL
)	NULL
and	NULL
PolyA	NULL
Tract	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
according	NULL
to	NULL
the	NULL
protocol	NULL
recommended	NULL
by	NULL
the	NULL
manufacturers	NULL
.	NULL

Gel	NULL
electrophoresis	NULL
,	NULL
transfer	NULL
onto	NULL
nylon	NULL
membranes	NULL
,	NULL
and	NULL
hybridization	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Johnson	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
probes	NULL
used	NULL
were	NULL
cDNA	NULL
fragments	NULL
from	NULL
the	NULL
following	NULL
plasmids	NULL
;	NULL
cyclin	NULL
D2	NULL
:	NULL
HindlII-Xbal	NULL
fragment	NULL
from	NULL
pRce/RSV-cyc	NULL
D2	NULL
(	NULL
Quelle	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
cyclin	NULL
D3	NULL
:	NULL
Spel-Xbal	NULL
fragment	NULL
from	NULL
pRe/RSV-cyc	NULL
D3	NULL
(	NULL
Quelle	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
cyclin	NULL
E	NULL
:	NULL
Asp718-Xbal	NULL
fragment	NULL
from	NULL
pRce/cye	NULL
E	NULL
(	NULL
Hinds	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
cyclin	NULL
E2	NULL
:	NULL
BamHI	NULL
fragment	NULL
from	NULL
pKS-HCN1	NULL
(	NULL
Lauper	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
,	NULL
cyclin	NULL
A	NULL
:	NULL
HindlII-BamHI	NULL
fragment	NULL
from	NULL
pCMX-A	NULL
,	NULL
edk2	NULL
,	NULL
edk4	NULL
,	NULL
edk6	NULL
,	NULL
cdc2	NULL
:	NULL
-	NULL
BamHI	NULL
_	NULL
fragment	NULL
-	NULL
from	NULL
_-	NULL
pCMVedk2WT-HA	NULL
,	NULL
pCMVedk4WT-HA	NULL
,	NULL
-	NULL
pCMVedk6WT-HA	NULL
,	NULL
pCMVedc2WT	NULL
,	NULL
respectively	NULL
(	NULL
van	NULL
den	NULL
Heuvel	NULL
and	NULL
Harlow	NULL
,	NULL
1993	NULL
)	NULL
,	NULL
E2F1	NULL
:	NULL
BamHI	NULL
fragment	NULL
from	NULL
pDCE2F	NULL
(	NULL
Johnson	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
E2F2	NULL
,	NULL
E2F3	NULL
:	NULL
-	NULL
BamHI	NULL
-	NULL
fragment	NULL
-	NULL
from	NULL
-	NULL
pCMVE2F-2	NULL
(	NULL
85-437	NULL
)	NULL
,	NULL
pCMVE2F-3	NULL
(	NULL
132-425	NULL
)	NULL
,	NULL
respectively	NULL
(	NULL
Lees	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
E2F4	NULL
;	NULL
BamHI-EcoRI	NULL
fragment	NULL
from	NULL
pCMV-E2F-4	NULL
(	NULL
Ginsberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
p15	NULL
``	NULL
;	NULL
EcoRI-HindlII	NULL
fragment	NULL
from	NULL
pBSp15	NULL
,	NULL
pl8	NULL
``	NULL
~**	NULL
:	NULL
Apal-Sacl	NULL
fragment	NULL
from	NULL
pTApl18	NULL
,	NULL
pl9	NULL
``	NULL
N®	NULL
``	NULL
;	NULL
BamHI-HindlII	NULL
fragment	NULL
from	NULL
pBSp19	NULL
,	NULL
Clal-Xbal	NULL
fragment	NULL
from	NULL
pBS-p21	NULL
(	NULL
DeGregori	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
p27	NULL
``	NULL
:	NULL
HindlII-Xbal	NULL
fragment	NULL
from	NULL
pBS-p27	NULL
(	NULL
DeGregori	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

pBSp15	NULL
and	NULL
pTAp18	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
G	NULL
Peters	NULL
.	NULL

pBSp19	NULL
was	NULL
made	NULL
by	NULL
cloning	NULL
of	NULL
nt	NULL
210-796	NULL
of	NULL
p19	NULL
2065	NULL
Oncogene	NULL
Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
2066	NULL
cDNA	NULL
into	NULL
the	NULL
EcoRV	NULL
site	NULL
of	NULL
pBSK-	NULL
using	NULL
RT-PCR	NULL
with	NULL
MOLT-4	NULL
mRNA	NULL
as	NULL
a	NULL
template	NULL
.	NULL

GAPDH	NULL
cDNA	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
probe	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
exposed	NULL
to	NULL
an	NULL
imaging	NULL
plate	NULL
20408	NULL
and	NULL
analysed	NULL
with	NULL
an	NULL
image	NULL
analyser	NULL
BAS	NULL
1500	NULL
.	NULL

Antibodies	NULL
and	NULL
immunoblotting	NULL
Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
with	NULL
minor	NULL
modifications	NULL
(	NULL
Iwanaga	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1999	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cell	NULL
lysates	NULL
prepared	NULL
from	NULL
Kit	NULL
225	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
recombinant	NULL
adenoviruses	NULL
were	NULL
resolved	NULL
by	NULL
electrophoresis	NULL
on	NULL
a	NULL
6	NULL
%	NULL
(	NULL
for	NULL
pRb	NULL
,	NULL
p107	NULL
and	NULL
p130	NULL
)	NULL
,	NULL
10	NULL
%	NULL
(	NULL
for	NULL
CDK2	NULL
,	NULL
CDK4	NULL
,	NULL
CDK6	NULL
,	NULL
cyclin	NULL
D2	NULL
,	NULL
cyclin	NULL
D3	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
p27	NULL
``	NULL
and	NULL
E2F1	NULL
)	NULL
or	NULL
15	NULL
%	NULL
(	NULL
for	NULL
p18	NULL
``	NULL
~**	NULL
,	NULL
p19N**	NULL
and	NULL
p219	NULL
``	NULL
``	NULL
)	NULL
SDS-polyacrylamide	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
polyvinylidene	NULL
difluoride	NULL
membranes	NULL
(	NULL
Atto	NULL
)	NULL
.	NULL

After	NULL
blocking	NULL
with	NULL
Block	NULL
Ace	NULL
(	NULL
Dainihonseiyaku	NULL
)	NULL
(	NULL
for	NULL
CDK2	NULL
,	NULL
CDK4	NULL
,	NULL
CDK6	NULL
,	NULL
cyclin	NULL
E	NULL
,	NULL
E2FI	NULL
,	NULL
p18	NULL
``	NULL
~**	NULL
``	NULL
and	NULL
p19	NULL
``	NULL
~*	NULL
``	NULL
)	NULL
or	NULL
5	NULL
%	NULL
skim	NULL
milk	NULL
(	NULL
GIBCO	NULL
BRL	NULL
)	NULL
in	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
(	NULL
for	NULL
pRb	NULL
,	NULL
p107	NULL
,	NULL
p130	NULL
,	NULL
p27	NULL
``	NULL
,	NULL
cyclin	NULL
D2	NULL
and	NULL
cyclin	NULL
D3	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
washing	NULL
with	NULL
PBS	NULL
,	NULL
the	NULL
blots	NULL
were	NULL
incubated	NULL
with	NULL
primary	NULL
antibodies	NULL
against	NULL
p107	NULL
(	NULL
sc-318	NULL
)	NULL
,	NULL
p130	NULL
(	NULL
sc-317	NULL
)	NULL
,	NULL
CDK2	NULL
(	NULL
sc-163-G	NULL
)	NULL
,	NULL
CDK4	NULL
(	NULL
sc-601-G	NULL
)	NULL
,	NULL
CDK6	NULL
(	NULL
se-177-G	NULL
)	NULL
,	NULL
p18	NULL
``	NULL
(	NULL
se-865	NULL
)	NULL
,	NULL
cyclin	NULL
D2	NULL
(	NULL
sc-452	NULL
)	NULL
,	NULL
cyclin	NULL
D3	NULL
(	NULL
sc-453	NULL
)	NULL
(	NULL
which	NULL
were	NULL
used	NULL
at	NULL
1	NULL
:	NULL
1000	NULL
)	NULL
,	NULL
pRb	NULL
(	NULL
se-50	NULL
)	NULL
,	NULL
p27	NULL
``	NULL
(	NULL
sc-1641	NULL
)	NULL
(	NULL
which	NULL
were	NULL
used	NULL
at	NULL
1:3000	NULL
)	NULL
,	NULL
p21	NULL
(	NULL
sc-6246	NULL
)	NULL
used	NULL
at	NULL
1:50	NULL
,	NULL
E2F1	NULL
(	NULL
sc-251	NULL
)	NULL
used	NULL
at	NULL
1:60	NULL
,	NULL
(	NULL
65911A	NULL
)	NULL
,	NULL
cyclin	NULL
E	NULL
(	NULL
14591¢	NULL
)	NULL
(	NULL
which	NULL
were	NULL
used	NULL
at	NULL
1	NULL
:	NULL
1000	NULL
)	NULL
,	NULL
in	NULL
10	NULL
%	NULL
Block	NULL
Ace	NULL
in	NULL
water	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
or	NULL
0.25	NULL
%	NULL
skim	NULL
milk	NULL
in	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
for	NULL
overnight	NULL
at	NULL
4°C	NULL
and	NULL
then	NULL
washed	NULL
with	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
.	NULL

These	NULL
References	NULL
Akagi	NULL
T	NULL
,	NULL
Ono	NULL
H	NULL
and	NULL
Shimotohno	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
86	NULL
,	NULL
4243-4249	NULL
.	NULL

Akagi	NULL
T	NULL
,	NULL
Ono	NULL
H	NULL
and	NULL
Shimotohno	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
12	NULL
,	NULL
1645-1652	NULL
.	NULL

DeGregori	NULL
J	NULL
,	NULL
Leone	NULL
G	NULL
,	NULL
Ohtani	NULL
K	NULL
,	NULL
Miron	NULL
A	NULL
and	NULL
Nevins	NULL
JR.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
,	NULL
2873-2887	NULL
.	NULL

Dyson	NULL
N.	NULL
(	NULL
1998	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
12	NULL
,	NULL
2245-2262	NULL
.	NULL

Ewen	NULL
ME	NULL
,	NULL
Sluss	NULL
HK	NULL
,	NULL
Sherr	NULL
CJ	NULL
,	NULL
Matsushime	NULL
H	NULL
,	NULL
Kato	NULL
J	NULL
and	NULL
Livingston	NULL
DM	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
73	NULL
,	NULL
487-497	NULL
.	NULL

Felber	NULL
BK	NULL
,	NULL
Paskaris	NULL
H	NULL
,	NULL
Kleinman-Ewing	NULL
C	NULL
,	NULL
Wong-Staal	NULL
F	NULL
and	NULL
Pavlakis	NULL
GN	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
229	NULL
,	NULL
675-679	NULL
.	NULL

Gessain	NULL
A	NULL
,	NULL
Barin	NULL
F	NULL
,	NULL
Vernant	NULL
JC	NULL
,	NULL
Gout	NULL
O	NULL
,	NULL
Maurs	NULL
L	NULL
,	NULL
Calender	NULL
A	NULL
and	NULL
de	NULL
The	NULL
G.	NULL
(	NULL
1985	NULL
)	NULL
.	NULL

Lancet	NULL
,	NULL
ii	NULL
,	NULL
407-410	NULL
.	NULL

Ginsberg	NULL
D	NULL
,	NULL
Vairo	NULL
G	NULL
,	NULL
Chittenden	NULL
T	NULL
,	NULL
Xiao	NULL
ZX	NULL
,	NULL
Xu	NULL
G	NULL
,	NULL
Wydner	NULL
KL	NULL
,	NULL
DeCaprio	NULL
JA	NULL
,	NULL
Lawrence	NULL
JB	NULL
and	NULL
Livingston	NULL
DM	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
8	NULL
,	NULL
2665-2679	NULL
.	NULL

Graham	NULL
FL	NULL
,	NULL
Smiley	NULL
J	NULL
,	NULL
Russell	NULL
WC	NULL
and	NULL
Nairn	NULL
R.	NULL
(	NULL
1977	NULL
)	NULL
.	NULL

J.	NULL
Gen	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
36	NULL
,	NULL
59-74	NULL
.	NULL

Grassmann	NULL
R	NULL
,	NULL
Dengler	NULL
C	NULL
,	NULL
Muller-Fleckenstein	NULL
I	NULL
,	NULL
Flecken-stein	NULL
B	NULL
,	NULL
McGuire	NULL
K	NULL
,	NULL
Dokhelar	NULL
MC	NULL
,	NULL
Sodroski	NULL
JG	NULL
and	NULL
Haseltine	NULL
WA	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
,	NULL
3351-3355	NULL
.	NULL

Grossman	NULL
WJ	NULL
,	NULL
Kimata	NULL
JT	NULL
,	NULL
Wong	NULL
FH	NULL
,	NULL
Zutter	NULL
M	NULL
,	NULL
Ley	NULL
TJ	NULL
and	NULL
Ratner	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
,	NULL
1057	NULL
1061	NULL
.	NULL

Hinds	NULL
PW	NULL
,	NULL
Mittnacht	NULL
S	NULL
,	NULL
Dulic	NULL
V	NULL
,	NULL
Arnold	NULL
A	NULL
,	NULL
Reed	NULL
SI	NULL
and	NULL
Weinberg	NULL
RA	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
70	NULL
,	NULL
993-1006	NULL
.	NULL

Hinuma	NULL
Y	NULL
,	NULL
Nagata	NULL
K	NULL
,	NULL
Hanaoka	NULL
M	NULL
,	NULL
Nakai	NULL
M	NULL
,	NULL
Matsumoto	NULL
T	NULL
,	NULL
Kinoshita	NULL
KI	NULL
,	NULL
Shirakawa	NULL
S	NULL
and	NULL
Miyoshi	NULL
I	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
78	NULL
,	NULL
6476-6480	NULL
.	NULL

Oncogene	NULL
antibodies	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
except	NULL
for	NULL
anti-p19	NULL
``	NULL
~*	NULL
``	NULL
and	NULL
anti-cyclin	NULL
E	NULL
antibodies	NULL
from	NULL
Pharmingen	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
peroxidase-labeled	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
1	NULL
:	NULL
5000	NULL
,	NULL
NA9310	NULL
,	NULL
Amersham	NULL
)	NULL
(	NULL
for	NULL
anti-cyclin	NULL
E	NULL
,	NULL
anti-p19N	NULL
``	NULL
``	NULL
,	NULL
and	NULL
anti-E2F1	NULL
)	NULL
,	NULL
anti-rabbit	NULL
IgG	NULL
(	NULL
1:5000	NULL
,	NULL
NA934	NULL
,	NULL
Amersham	NULL
)	NULL
(	NULL
for	NULL
anti-pRb	NULL
,	NULL
anti-p107	NULL
,	NULL
anti-p130	NULL
,	NULL
anti-p18	NULL
``	NULL
~	NULL
``	NULL
*	NULL
``	NULL
,	NULL
anti-cyclin	NULL
D2	NULL
and	NULL
anti-cyclin	NULL
D3	NULL
)	NULL
,	NULL
or	NULL
anti-goat	NULL
IgG	NULL
(	NULL
1	NULL
:	NULL
5000	NULL
,	NULL
6025-05	NULL
,	NULL
Southern	NULL
Biotech	NULL
)	NULL
(	NULL
for	NULL
anti-CDK2	NULL
,	NULL
anti-CDK4	NULL
and	NULL
anti-CDK6	NULL
)	NULL
,	NULL
in	NULL
10	NULL
%	NULL
Block	NULL
Ace	NULL
in	NULL
water	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
or	NULL
0.05	NULL
%	NULL
skim	NULL
milk	NULL
in	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
then	NULL
washed	NULL
with	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
and	NULL
finally	NULL
with	NULL
PBS	NULL
alone	NULL
.	NULL

Proteins	NULL
recognized	NULL
by	NULL
the	NULL
antibodies	NULL
were	NULL
visualized	NULL
using	NULL
the	NULL
enhanced	NULL
chemiluminescence	NULL
Western	NULL
blotting	NULL
detection	NULL
system	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
J	NULL
Hamuro	NULL
for	NULL
IL-2	NULL
,	NULL
B	NULL
Amati	NULL
and	NULL
G	NULL
Peters	NULL
for	NULL
plasmids	NULL
and	NULL
M	NULL
Yoshida	NULL
for	NULL
recombinant	NULL
adenoviruses	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
Grant-in-Aid	NULL
for	NULL
General	NULL
Scientific	NULL
Research	NULL
and	NULL
Cancer	NULL
Research	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Education	NULL
,	NULL
Science	NULL
,	NULL
Sports	NULL
and	NULL
Culture	NULL
,	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
CREST	NULL
(	NULL
Core	NULL
Research	NULL
for	NULL
Evolutional	NULL
Science	NULL
and	NULL
Technology	NULL
)	NULL
of	NULL
the	NULL
Japan	NULL
Science	NULL
and	NULL
Technology	NULL
Corporation	NULL
(	NULL
JST	NULL
)	NULL
,	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
NOVARTIS	NULL
Foundation	NULL
(	NULL
Japan	NULL
)	NULL
for	NULL
the	NULL
Promotion	NULL
of	NULL
Science	NULL
,	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
Osaka	NULL
Cancer	NULL
Foundation	NULL
,	NULL
and	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
The	NULL
Naito	NULL
Foundation	NULL
.	NULL

Hirai	NULL
H	NULL
,	NULL
Fujisawa	NULL
J	NULL
,	NULL
Suzuki	NULL
T	NULL
,	NULL
Ueda	NULL
K	NULL
,	NULL
Muramatsu	NULL
M	NULL
,	NULL
Tsuboi	NULL
A	NULL
,	NULL
Arai	NULL
N	NULL
and	NULL
Yoshida	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
7	NULL
,	NULL
1737-1742	NULL
.	NULL

Hori	NULL
T	NULL
,	NULL
Uchiyama	NULL
T	NULL
,	NULL
Tsudo	NULL
M	NULL
,	NULL
Umadome	NULL
H	NULL
,	NULL
Ohno	NULL
H	NULL
,	NULL
Fukuhara	NULL
S	NULL
,	NULL
Kita	NULL
K	NULL
and	NULL
Uchino	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
70	NULL
,	NULL
1069-1072	NULL
.	NULL

Hoshikawa	NULL
Y	NULL
,	NULL
Mori	NULL
A	NULL
,	NULL
Amimoto	NULL
K	NULL
,	NULL
Iwabe	NULL
K	NULL
and	NULL
Hatakeyama	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
95	NULL
,	NULL
8574-8579	NULL
.	NULL

Ikeda	NULL
MA	NULL
,	NULL
Jakoi	NULL
L	NULL
and	NULL
Nevins	NULL
JR.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
3215-3220	NULL
.	NULL

Iwanaga	NULL
Y	NULL
,	NULL
Tsukahara	NULL
T	NULL
,	NULL
Ohashi	NULL
T	NULL
,	NULL
Tanaka	NULL
Y	NULL
,	NULL
Arai	NULL
M	NULL
,	NULL
Nakamura	NULL
M	NULL
,	NULL
Ohtani	NULL
K	NULL
,	NULL
Koya	NULL
Y	NULL
,	NULL
Kannagi	NULL
M	NULL
,	NULL
Yamamo-to	NULL
N	NULL
and	NULL
Fujii	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
73	NULL
,	NULL
1271-1277	NULL
.	NULL

Johnson	NULL
DG	NULL
,	NULL
Ohtani	NULL
K	NULL
and	NULL
Nevins	NULL
JR.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
8	NULL
,	NULL
1514-1525	NULL
.	NULL

Johnson	NULL
DG	NULL
,	NULL
Schwarz	NULL
JK	NULL
,	NULL
Cress	NULL
WD	NULL
and	NULL
Nevins	NULL
JR.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
365	NULL
,	NULL
349-352	NULL
.	NULL

LaBaer	NULL
J	NULL
,	NULL
Garrett	NULL
MD	NULL
,	NULL
Stevenson	NULL
LF	NULL
,	NULL
Slingerland	NULL
JM	NULL
,	NULL
Sandhu	NULL
C	NULL
,	NULL
Chou	NULL
HS	NULL
,	NULL
Fattaey	NULL
A	NULL
and	NULL
Harlow	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
11	NULL
,	NULL
847-862	NULL
.	NULL

Lauper	NULL
N	NULL
,	NULL
Beck	NULL
AR	NULL
,	NULL
Cariou	NULL
S	NULL
,	NULL
Richman	NULL
L	NULL
,	NULL
Hofmann	NULL
K	NULL
,	NULL
Reith	NULL
W	NULL
,	NULL
Slingerland	NULL
JM	NULL
and	NULL
Amati	NULL
B	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
17	NULL
,	NULL
2637-2643	NULL
.	NULL

Lee	NULL
B	NULL
,	NULL
Tanaka	NULL
Y	NULL
and	NULL
Tozawa	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Tohoku	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
157	NULL
,	NULL
1-11	NULL
.	NULL

Lees	NULL
JA	NULL
,	NULL
Saito	NULL
M	NULL
,	NULL
Vidal	NULL
M	NULL
,	NULL
Valentine	NULL
M	NULL
,	NULL
Look	NULL
T	NULL
,	NULL
Harlow	NULL
E	NULL
,	NULL
Dyson	NULL
N	NULL
and	NULL
Helin	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
13	NULL
,	NULL
7813-7825	NULL
.	NULL

Low	NULL
KG	NULL
,	NULL
Dorner	NULL
LF	NULL
,	NULL
Fernando	NULL
DB	NULL
,	NULL
Grossman	NULL
J	NULL
,	NULL
Jeang	NULL
KT	NULL
and	NULL
Comb	NULL
MJ	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
71	NULL
,	NULL
1956-1962	NULL
.	NULL

Minowada	NULL
J	NULL
,	NULL
Onuma	NULL
T	NULL
and	NULL
Moore	NULL
GE	NULL
.	NULL

(	NULL
1972	NULL
)	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

,	NULL
49	NULL
,	NULL
891-895	NULL
.	NULL

Miyoshi	NULL
I	NULL
,	NULL
Kubonishi	NULL
I	NULL
,	NULL
Yoshimoto	NULL
S	NULL
,	NULL
Akagi	NULL
T	NULL
,	NULL
Ohtsuki	NULL
Y	NULL
,	NULL
Shiraishi	NULL
Y	NULL
,	NULL
Nagata	NULL
K	NULL
and	NULL
Hinuma	NULL
Y	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
294	NULL
,	NULL
770-771	NULL
.	NULL

Nerenberg	NULL
M	NULL
,	NULL
Hinrichs	NULL
SH	NULL
,	NULL
Reynolds	NULL
RK	NULL
,	NULL
Khoury	NULL
G	NULL
and	NULL
Jay	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
237	NULL
,	NULL
1324-1329	NULL
.	NULL

Nevins	NULL
JR.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
258	NULL
,	NULL
424-429	NULL
.	NULL

Ohtani	NULL
K	NULL
,	NULL
Iwanaga	NULL
R	NULL
,	NULL
Arai	NULL
M	NULL
,	NULL
Huang	NULL
Y	NULL
,	NULL
Matsumura	NULL
Y	NULL
and	NULL
Nakamura	NULL
M.	NULL
(	NULL
2000	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
275	NULL
,	NULL
11154-11163	NULL
.	NULL

Osame	NULL
M	NULL
,	NULL
Igata	NULL
A	NULL
,	NULL
Usuku	NULL
K	NULL
,	NULL
Rosales	NULL
RL	NULL
and	NULL
Matsumoto	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
.	NULL

Lancet	NULL
,	NULL
i	NULL
,	NULL
1031-1032	NULL
.	NULL

Poiesz	NULL
BJ	NULL
,	NULL
Ruscetti	NULL
FW	NULL
,	NULL
Gazdar	NULL
AF	NULL
,	NULL
Bunn	NULL
PA	NULL
,	NULL
Minna	NULL
JD	NULL
and	NULL
Gallo	NULL
RC	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
,	NULL
7415-7419	NULL
.	NULL

Quelle	NULL
DE	NULL
,	NULL
Ashmun	NULL
RA	NULL
,	NULL
Shurtleff	NULL
SA	NULL
,	NULL
Kato	NULL
JY	NULL
,	NULL
Bar-Sagi	NULL
D	NULL
,	NULL
Roussel	NULL
MF	NULL
and	NULL
Sherr	NULL
CJ	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
,	NULL
1559	NULL
1571	NULL
.	NULL

Schwarz	NULL
JK	NULL
,	NULL
Bassing	NULL
CH	NULL
,	NULL
Kovesdi	NULL
I	NULL
,	NULL
Datto	NULL
MB	NULL
,	NULL
Blazing	NULL
M	NULL
,	NULL
George	NULL
S	NULL
,	NULL
Wang	NULL
XF	NULL
and	NULL
Nevins	NULL
JR.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
,	NULL
483-487	NULL
.	NULL

Mechanism	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
R	NULL
Iwanaga	NULL
et	NULL
al	NULL
Seiki	NULL
M	NULL
,	NULL
Hattori	NULL
S	NULL
,	NULL
Hirayama	NULL
Y	NULL
and	NULL
Yoshida	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
5	NULL
,	NULL
561-565	NULL
.	NULL

Smith	NULL
EJ	NULL
,	NULL
Leone	NULL
G	NULL
,	NULL
DeGregori	NULL
J	NULL
,	NULL
Jakoi	NULL
L	NULL
and	NULL
Nevins	NULL
JR.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
,	NULL
6965-6976	NULL
.	NULL

Sodroski	NULL
J	NULL
,	NULL
Rosen	NULL
C	NULL
,	NULL
Goh	NULL
WC	NULL
and	NULL
Haseltine	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
228	NULL
,	NULL
1430-1434	NULL
.	NULL

Suzuki	NULL
T	NULL
,	NULL
Kitao	NULL
S	NULL
,	NULL
Matsushime	NULL
H	NULL
and	NULL
Yoshida	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
15	NULL
,	NULL
1607-1614	NULL
.	NULL

Suzuki	NULL
T	NULL
,	NULL
Narita	NULL
T	NULL
,	NULL
Uchida-Toita	NULL
M	NULL
and	NULL
Yoshida	NULL
M.	NULL
(	NULL
1999	NULL
)	NULL
.	NULL

Virology	NULL
,	NULL
259	NULL
,	NULL
384-391	NULL
.	NULL

Tanaka	NULL
A	NULL
,	NULL
Takahashi	NULL
C	NULL
,	NULL
Yamaoka	NULL
S	NULL
,	NULL
Nosaka	NULL
T	NULL
,	NULL
Maki	NULL
M	NULL
and	NULL
Hatanaka	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
,	NULL
1071-1075.	NULL
van	NULL
den	NULL
Heuvel	NULL
S	NULL
and	NULL
Harlow	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
262	NULL
,	NULL
2050	NULL
2054	NULL
.	NULL

Yoshida	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

Clin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
121	NULL
,	NULL
521-528	NULL
.	NULL

Yoshida	NULL
M	NULL
,	NULL
Miyoshi	NULL
I	NULL
and	NULL
Hinuma	NULL
Y	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
79	NULL
,	NULL
2031-2035	NULL
.	NULL

2067	NULL
Oncogene	NULL

